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CAD Coronary artery disease 
NSTEMI Non-ST-elevation myocardial infarction 
CCTA Coronary computed tomography angiography 
ECG Electrocardiography 
STEMI ST-elevation myocardial infarction 
MINOCA Myocardial infarction with non-obstructive coronary arteries 
INOCA Ischemia and no obstructive coronary artery disease 
MicroCAD  Myocardial Ischemia in Non-obstructive Coronary Artery Disease 
CT Computed tomography 
HbA1c Haemologlobin A1c 
OR Odds ratio 
CI Confidence interval 
β Standardized beta coefficient  
SPECT Single photon emission computed tomography  
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2. Scientific environment 
The present thesis is based on a collaboration between The Bergen Hypertension and 
Cardiac Dynamics Group, Department of Clinical Science at the University of Bergen 
and the Department of Heart Disease, Haukeland University Hospital in Bergen, 
Norway. The work is based on two clinical studies carried out at Department of Heart 
Disease during the years 2008-2014.  
 The Bergen Hypertension and Cardiac Dynamics Group integrates 
researchers from the Department of Clinical Science, University of Bergen and at 
Department of Heart Disease, Haukeland University Hospital. The group is chaired 
by Professor Eva Gerdts. Principal investigators include Professor Mai Tone 
Lønnebakken and Professor Knut Matre. In addition, there are two post-doctoral 
fellows, seven PhD fellows, one student in the Medial Student Research Programme 
and several master students in the group. The group uses echocardiography as a main 
method in clinical and experimental research, in addition to vascular ultrasound, 
applanation tonometry, ambulatory blood pressure monitoring and coronary 
computed tomography angiography. The main fields of interest are hypertensive heart 
disease and sex differences in cardiovascular disease. The group has extensive 
international and national collaboration, including NORHEART – the Norwegian 
PhD School of Heart Research. The Medical Student Research Programme at The 
Faculty of Medicine in the University of Bergen provides medical students the 
possibility to engage in research as a part of their education. Study 1 in this thesis was 
completed as a part of the Medical Student Research Programme.  
 A collaboration with the MTA-SE Cardiovascular Imaging Research Group at 
the Heart and Vascular Centre of Semmelweis University in Budapest, Hungary 
chaired by Assistant Professor Pál Maurovich-Horvat, MD, PhD was established 
during the work with study 3 in this thesis. The research group is a multidisciplinary 
team including cardiologist, radiologist, computer scientist and PhD-students. Their 
focus is to improve cardiovascular risk assessment, and the group is world-leading in 
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Background: The underlying mechanisms causing myocardial ischemia in non-
obstructive coronary artery disease (CAD) are incompletely understood. We tested 
whether the total coronary artery plaque burden, coronary tortuosity and left 
ventricular hypertrophy were independently associated with myocardial ischemia.  
Material and methods: Study 1 included 108 patients with non-ST-elevation 
myocardial infarction (NSTEMI), and coronary artery plaque burden and tortuosity 
were assessed by quantitative invasive coronary angiography. Study 2 included 132 
symptomatic patients with non-obstructive CAD by coronary computed tomography 
angiography (CCTA), and left ventricular hypertrophy was determined by 
echocardiography. In study 3, coronary artery plaque burden was assessed by 
quantitative CCTA in 125 symptomatic patients with non-obstructive CAD. 
Myocardial ischemia was determined using myocardial contrast echocardiography at 
rest in study 1 and during pharmacological stress in study 2 and 3. 
Results: In study 1, coronary artery plaque burden was associated with severe 
myocardial ischemia independent of angiographic stenosis severity and 
cardiovascular risk factors. No association was found between coronary artery 
tortuosity and ischemia. In study 2, left ventricular hypertrophy was associated with 
myocardial ischemia, independent of cardiovascular risk factors and coronary 
calcium score. In study 3, coronary artery plaque burden estimated by CCTA was 
associated with myocardial ischemia, independent of left ventricular mass index, 
coronary calcium score and cardiovascular risk factors. 
Conclusion: Coronary artery plaque burden was independently associated with 
myocardial ischemia both in NSTEMI and in symptomatic patients with non-
obstructive CAD. Left ventricular hypertrophy was independently associated with 
myocardial ischemia in patients with non-obstructive CAD. These results suggest that 
the coronary plaque burden and left ventricular hypertrophy may contribute to 
myocardial ischemia independent of CAD severity.   
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6. Introduction 
Ischemic heart disease is a leading cause of death of women and men in the world 
(1). Non-obstructive coronary artery disease (CAD) has traditionally been regarded as 
a benign condition, unlikely to cause myocardial ischemia. However, patients with 
non-obstructive CAD (angiographic coronary stenosis diameter reduction <50%) 
have increased risk of myocardial infarction (2) and death (3). Myocardial ischemia 
has also been demonstrated in patients with non-obstructive CAD and this is related 
to impaired prognosis (4-7). Non-obstructive CAD is two-fold more common in 
women than in men with non-ST-elevation myocardial infarction (NSTEMI) (8). 
Further, non-obstructive CAD or normal coronary arteries is found in the majority of 
patients undergoing coronary computed tomography angiography (CCTA) due to 
suspected ischemic heart disease (9). Myocardial ischemia results from a mismatch 
between the oxygen supply and the oxygen demand of the myocardium (10). The 
underlying mechanisms of myocardial ischemia in non-obstructive CAD are not fully 
understood (11, 12). Consequently, the management of non-obstructive CAD remains 
a puzzle for clinical practice as there is a lack of evidence-based treatment. 
 In order to obtain personalized treatment and improve outcome in non-
obstructive CAD, it is of the utmost importance to identify the underlying causes of 
myocardial ischemia (11, 13). It is likely that several mechanisms that may lower the 
oxygen supply or increase the oxygen demand contribute to myocardial ischemia in 
non-obstructive CAD (11, 14-16). Coronary artery tortuosity is known as twist and 
bends of the coronary arteries and has been suggested to reduce perfusion pressure 
(17-20). In addition, the coronary atherosclerotic plaque burden, reflecting the extent 
of atherosclerosis, has been associated with myocardial ischemia in non-obstructive 
CAD (21). Left ventricular hypertrophy, which is a hallmark of hypertension-
mediated organ damage, leads to increased myocardial oxygen demand and may 
lower the threshold for occurrence of myocardial ischemia (22, 23).  
 This thesis explored the association of coronary artery tortuosity, coronary 
artery plaque burden and left ventricular hypertrophy with myocardial ischemia in 
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patients with NSTEMI and in symptomatic patients with non-obstructive CAD by 
CCTA.   
6.1 Non-obstructive coronary artery disease 
In spite of the decline in mortality rates during the past 50 years, ischemic heart 
disease remains a major cause of death worldwide in both women and men (1). 
Ischemic heart disease is characterized by an imbalance between the amount of 
oxygen delivered to the myocardium and the myocardial oxygen demand. Ischemic 
heart disease is often caused by CAD, which is characterized by plaque formation 
through a complex interaction of intimal inflammation, necrosis, fibrosis, and 
calcification (24, 25). The development of CAD is closely linked with cardiovascular 
risk factors, such as age, sex, hypertension, diabetes mellitus, smoking, cholesterol 
level and obesity, although the exact etiology is complex and multifactorial (24, 25). 
CAD is a chronic, progressive condition that may remain asymptomatic, or manifest 
as an acute or chronic coronary syndrome (26-28). CAD is categorized as obstructive 
or non-obstructive according to the degree of luminal stenosis seen in invasive 
coronary angiography or CCTA (Figure 1).  
Figure 1. Schematic figure of visual assessment of normal coronary artery, non-
obstructive and obstructive coronary artery disease  
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Obstructive CAD is defined when plaque-associated arterial lumen diameter 
reduction ≥ 50% compared with a healthy proximal segment of the coronary artery is 
found, while non-obstructive CAD is considered present if the plaque causes < 50% 
arterial lumen diameter reduction (Figure 1). Ever since the seminal animal studies of 
Gould and Lipscomb during the 1970s showed that the blood supply to the 
myocardium was reduced during exercise when there was an obstruction in the 
coronary artery (29, 30), the clinical management of patients with suspected acute or 
chronic ischemic heart disease has centered on detection and treatment of obstructive 
CAD (26-28, 31, 32). Stenoses with lumen diameter reduction < 50% compared with 
a healthy proximal segment were for a long time regarded as “non-significant” and 
thought to be unlikely to cause myocardial ischemia. Accordingly, patients with non-
obstructive CAD were erroneously considered as free from ischemic heart disease. 
However, this paradigm fails to explain that patients with non-obstructive CAD have 
an impaired cardiovascular prognosis (33, 34) and may have objective evidence of 
myocardial ischemia (11, 21, 35). 
6.2 Clinical presentation of non-obstructive coronary artery 
disease 
Non-obstructive CAD is found in both acute and chronic coronary syndromes 
(36). Acute and chronic coronary syndromes are umbrella terms to describe patients 
presenting with acute or chronic chest pain of suspected ischemic origin (26-28). In 
acute coronary syndrome, electrocardiography (ECG) and troponin changes enable 
categorization in NSTEMI, ST-elevation myocardial infarction (STEMI) and unstable 
angina, given that other causes of chest pain are excluded (Figure 2) (26, 27). In 
patients with acute myocardial infarction, non-obstructive CAD is found in about 1 of 
10 patients (8, 36). In order to address this common clinical presentation, the clinical 
diagnosis “myocardial infarction with non-obstructive coronary arteries” (MINOCA) 
was introduced in 2016 (37) (Figure 2). For this diagnosis, three criteria must be 
fulfilled, namely myocardial infarction, non-obstructive CAD by coronary 
angiography (stenosis <50%) and no clinically overt specific cause for the acute 
presentation (37). MINOCA is particularly more common in women than in men, and 
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occurs both in NSTEMI and STEMI (8, 38-40). The prognosis of MINOCA has been 
somewhat inconsistently reported, but it is not benign (40-42). In a Swedish registry 
study including 9136 patients with MINOCA, 13% died during 4.1 years follow-up 
and 24% experienced a new major adverse cardiac event (41). Further, it has been 
demonstrated that patients with MINOCA had similar risk of death and repeated 
myocardial infarction as subjects with myocardial infarction with obstructive CAD 
(42). Moreover, cardiovascular risk factors and medical treatment may modify the 
prognosis (39, 41, 42). However, the underlying pathophysiological mechanisms of 
MINOCA are still incompletely understood, reflected in the lack of evidence-based 
treatment recommendations (37). 
Figure 2. Schematic presentation of ischemic heart disease with non-obstructive 
coronary artery disease   
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A common clinical scenario in chronic coronary syndromes is a patient presenting 
with “stable” symptoms of myocardial ischemia, where CAD is suspected of causing 
ischemic heart disease. The classic symptoms are retrosternal chest pain or dyspnoea 
that is precipitated by physical exercise. The symptoms typically disappear within 
minutes after abating exercise. In such patients, non-obstructive CAD is found in 30-
45% in recent CCTA studies, while normal coronary arteries are found in 28-36% 
(43-45). As CCTA is now recommended as an initial diagnostic test in symptomatic 
patients with low to intermediate pre-test probability of CAD, the number of patients 
diagnosed with non-obstructive CAD is expected to increase (28, 32). However, 
CCTA and coronary angiography provide only the anatomical evaluation of stenosis 
severity. Additional functional testing is therefore necessary to determine whether 
myocardial ischemia is present.  
 The term ischemia and no obstructive coronary artery disease (INOCA) has 
been suggested to describe patients with the triad of symptoms of ischemic heart 
disease, objective evidence of myocardial ischemia at rest or stress, and absence of 
obstructive CAD (11) (Figure 2). However, this term is currently not implemented as 
a clinical diagnosis by the current guidelines for chronic coronary syndrome (28). 
Symptomatic patients with non-obstructive CAD have an impaired prognosis 
compared with subjects with normal coronary arteries (4, 33, 36, 45, 46). For 
instance, during ten years follow-up of patients with suspected CAD undergoing 
CCTA, the risk of myocardial infarction or cardiac death was seven times higher in 
patients with non-obstructive CAD compared to patients with normal coronary 
arteries, after adjusting for cardiovascular risk factors (45). Further, non-obstructive 
CAD has been associated with increased cardiovascular death, risk of myocardial 
infarction and repeated hospitalization (4, 33, 36, 45). Importantly, patients with non-
obstructive CAD have reduced quality of life, possibly reflecting the current 
uncertainty in clinical management and lack of evidence-based care provided to these 
patients (47).  
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6.3 Myocardial ischemia in non-obstructive coronary artery 
disease 
Presence of myocardial ischemia has been shown to predict adverse prognosis in 
patients with non-obstructive CAD (4-7), but the underlying mechanisms of ischemia 
are not fully understood (11, 37, 48). Thus, in order to improve the prognosis of 
patients with non-obstructive CAD, there is a need to further understand the 
underlying mechanisms of myocardial ischemia. Myocardial ischemia occurs when 
there is an imbalance between the amount of oxygen supplied to the myocardium and 
the myocardial oxygen demand (Figure 3).  
Figure 3. Myocardial ischemia resulting from a mismatch between oxygen 
supply and demand  
 
Myocardial oxygen supply depends on the oxygen carriage ability of the blood, 
coronary artery blood flow, and myocardial oxygen extraction, while the myocardial 
oxygen demand is dependent on heart rate, contractility, and left ventricular wall 
stress (10). Detection of myocardial ischemia is a cornerstone in the clinical 
management of patients with suspected acute or chronic ischemic heart disease, and 
several diagnostic imaging modalities are recommended, including contrast-enhanced 
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echocardiography (26-28, 32, 49).  
  Myocardial infarction occurs when acute myocardial ischemia leads to 
necrosis of the myocardial cells (50). Following the universal definitions, myocardial 
infarction can be categorized according to the underlying pathophysiological 
mechanisms (50). Acute myocardial ischemia is most often caused by a sudden 
decrease in coronary blood flow (14). The predominant cause of decreased coronary 
blood flow is coronary artery luminal occlusion due to thrombosis caused by plaque 
rupture or erosion (25, 51). Interestingly, the culprit plaque is most often non-
obstructive (25, 51, 52). A mismatch between myocardial oxygen supply and demand 
may also cause myocardial infarction (Figure 3). Other mechanisms that may 
contribute to an acute reduction in oxygen supply include coronary vasospasm, 
coronary dissection and microvascular spasm (53, 54). On the other hand, acute 
increased oxygen demand may result from a variety of other conditions, including 
tachyarrhythmias and hypertension (Figure 3) (55). Several of these mechanisms may 
contribute to MINOCA. However, there is still a knowledge gap regarding the 
underlying mechanisms of MINOCA, as the diagnostic work-up does not always 
provide an explanation of the myocardial infarction (12, 37).  
 Chronic myocardial ischemia occurs when there is a chronic mismatch 
between the oxygen supply and demand in the myocardium, and manifests as a 
chronic coronary syndrome (28). Myocardial ischemia may occur only when the 
myocardial oxygen demand is increased, such as during exercise or psychological 
stress. As the oxygen extraction is near maximum at rest, coronary artery blood flow 
must increase in response to increased oxygen demand. This increase in coronary 
blood flow may be limited due to obstructive CAD, resulting in chronic myocardial 
ischemia (14). Interestingly, it is well established that there may be a mismatch 
between the visual and functional significance of CAD by invasive coronary 
angiography (56). The hemodynamic impact of a coronary artery stenosis can be 
assessed with invasive measurements during coronary angiography. Fractional flow 
reserve determines the ratio between the blood pressure distal to a coronary stenosis 
and the pressure in the aorta during maximum hyperaemia, and is considered to 
induce myocardial ischemia when ≤0.80 (56). Importantly, abnormal fractional flow 
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reserve has been found in non-obstructive CAD (56, 57).  
 In addition to CAD, there are several mechanisms that may lead to a chronic 
imbalance between the oxygen supply and demand (11, 53, 58). For instance, 
microvascular dysfunction may underlie myocardial ischemia in patients with non-
obstructive CAD and predict adverse outcome (58, 59). The coronary 
microvasculature normally contributes to maintain the balance between oxygen 
supply and demand (60). For instance, during exercise the coronary arterioles will 
dilate to enable the necessary increase in myocardial blood flow. Several conditions 
may lead to microvascular dysfunction through structural or functional changes, 
including hypertension, left ventricular hypertrophy and diabetes (60). Microvascular 
dysfunction may contribute to myocardial ischemia through disturbing the 
mechanisms that normally ensure the balance between myocardial oxygen supply and 
demand. Moreover, vasospasms in the coronary arteries or in the microvasculature 
may reduce oxygen supply and contribute to INOCA (11, 58). In addition, an 
increased myocardial oxygen demand, caused by left ventricular hypertrophy, may 
lower the threshold of development of chronic myocardial ischemia (22) (Figure 3).  
  Although several mechanisms that may induce acute or chronic ischemia 
independent of CAD have been uncovered, there are still knowledge gaps regarding 
the underlying causes of ischemia in patients with non-obstructive CAD. For 
instance, whether coronary artery tortuosity (61), the total coronary artery plaque 
burden (21), and left ventricular hypertrophy impact myocardial ischemia in 
symptomatic patients with non-obstructive CAD is not fully explored.   
6.3.1 Coronary artery plaque burden  
The coronary artery plaque burden reflects the extent of coronary atherosclerosis. It 
can be estimated from visual assessment or quantified from coronary angiography or 
CCTA (62). It has been reported that the extent of non-obstructive CAD, taken as the 
number of coronary artery segments or number of coronary arteries with non-
obstructive CAD by CCTA, predicts impaired prognosis (63-66). Further, it has been 
demonstrated that higher coronary calcium score, which reflects the total burden of 
calcified coronary atherosclerosis, is associated with presence of myocardial ischemia 
in patients with suspected CAD (67). However, coronary calcium score does not 
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provide a quantification of the non-calcified atherosclerotic plaque. Non-calcified 
plaque has been associated with myocardial ischemia independent of stenosis severity 
in patients with suspected CAD (68). In addition, non-calcified plaque has been 
suggested as more likely to cause myocardial ischemia than calcified plaque (62). 
Quantitative CCTA provides quantification of both calcified and non-calcified 
plaque, thus more accurately reflecting the true anatomical atherosclerotic burden 
(62, 69, 70). However, few studies have investigated the association between the total 
plaque burden with myocardial ischemia in NSTEMI, or the impact of the total 
plaque burden on chronic ischemic heart disease in patients with non-obstructive 
CAD (21).  
6.3.2 Coronary artery tortuosity 
Coronary artery tortuosity is considered present when consecutive curvatures of the 
coronary arteries are found by coronary angiography (71, 72). Coronary artery 
tortuosity is in general considered an incidental benign finding, and is more common 
in women than in men (71-73). Coronary artery tortuosity has been associated with 
hypertension and aging, and has been suggested as a contributor to myocardial 
ischemia (71, 72). In fact, numerical studies have shown that coronary tortuosity may 
negatively impact myocardial perfusion (17-20). However, whether coronary 
tortuosity affects myocardial perfusion in humans is less explored (61).  
6.3.3 Left ventricular hypertrophy 
Left ventricular hypertrophy is characterized by abnormal growth of both the 
cardiomyocytes and the interstitial cells in the myocardium of the left ventricle (74). 
Typically, the left ventricle remodels in response to chronic changes in pressure and 
volume load, in addition to neurohumoral changes, including activation of the 
sympathetic nervous system and the renin-angiotensin-aldosterone system as seen in 
hypertension, diabetes, and obesity (75-78). Left ventricular hypertrophy can be 
detected by echocardiography (79). Importantly, left ventricular hypertrophy is a 
major predictor of increased cardiovascular morbidity and mortality in hypertensive 
subjects as well as in the general population (80-84). Left ventricular hypertrophy 
may contribute to myocardial ischemia through an increase in myocardial oxygen 
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demand caused by the higher myocardial mass (22). In addition, left ventricular 
hypertrophy may induce microvascular dysfunction (60). Left ventricular 
hypertrophy has been associated with larger infarction size in patients with STEMI 
(85), and with myocardial ischemia in a hypertensive patient with suspected ischemic 
heart disease and normal coronary angiography (35). However, the association of left 
ventricular hypertrophy with myocardial ischemia in symptomatic patients with non-
obstructive CAD has not been much studied. 
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7. Hypothesis and study aims  
 
1.1 Hypothesis 
We hypothesized that coronary artery plaque burden, coronary artery tortuosity, and 
left ventricular hypertrophy were associated with myocardial ischemia independent of 
cardiovascular risk factors in patients with NSTEMI or symptomatic non-obstructive 
CAD.   
1.2 Specific aims  
 Explore the association of coronary artery plaque burden and tortuosity with 
myocardial ischemia in NSTEMI patients. 
 Assess the association of left ventricular hypertrophy with myocardial 
ischemia in symptomatic patients with non-obstructive CAD. 
 Explore the association of coronary artery plaque burden with myocardial 
ischemia in symptomatic patients with non-obstructive CAD. 
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8. Materials and methods  
8.1 Study design and patient population 
8.1.1 Study 1  
Study 1 is a post-hoc analysis based on a cross-sectional study that was conducted to 
test the association of myocardial ischemia identified by resting contrast 
echocardiography with invasive coronary angiographic disease severity in patients 
with NSTEMI (86). The patients in study 1 were recruited from Department of Heart 
Disease, Haukeland University Hospital from March through December 2008. 
Inclusion criterion were NSTEMI, defined in accordance with the 2007 European 
guidelines, clinically scheduled coronary angiography and residency in the hospital 
catchment area (87).  Exclusion criteria were hemodynamic instability, development 
of ST-elevation in the electrocardiogram, mechanic valve prostheses, severe 
pulmonary disease or contradiction to coronary angiography. A total of 126 
consecutive patients hospitalized with NSTEMI and scheduled for coronary 
angiography within 72 hours after admittance were invited to participate (Figure 4).  
Figure 4. Flow chart of patients included in study 1  
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In total, 110 patients signed informed consent and underwent myocardial contrast 
echocardiography at rest before scheduled coronary angiography. For study 1, two 
patients were excluded from the analysis in because all native coronary arteries were 
occluded, leaving 108 patients eligible (Figure 4). 
8.1.2 Study 2  
Study 2 was a prospectively planned analysis. The participants in study 2 are from 
The Myocardial Ischemia in Non-obstructive Coronary Artery Disease (MicroCAD) 
study. The cross-sectional MicroCAD study was conducted to assess the presence of 
myocardial ischemia by myocardial contrast stress echocardiography and evaluate 
potential clinical markers of ischemia in symptomatic patients with non-obstructive 
CAD by CCTA. The participants were prospectively included from symptomatic 
patients who were referred to CCTA at the Department of Heart Disease, Haukeland 
University Hospital, Bergen, Norway after a clinical evaluation by cardiologists. The 
inclusion period was from May 2013 until November 2014.  
 Inclusion criteria were non-obstructive CAD, defined as at least one coronary 
artery stenosis with lumen diameter reduction 1-49%, age >30 years, chronic 
coronary syndrome, defined as exercise-induced chest pain and/or dyspnoea for ≥ 6 
months, and at least one cardiovascular risk factor (hypertension, 
hypercholesterolemia, diabetes, smoking or family history of premature CAD). 
 Exclusion criteria clinically unstable angina pectoris, severe valve disease, 
mechanical valve prosthesis, arrhythmias, severe pulmonary disease, known allergies 
to ultrasound contrast or pregnancy. The sample size of 132 patients was calculated in 
order to have 80% power with statistical level of 0.05 to find 50% differences in 
prevalence of cardiovascular risk factors, including left ventricular hypertrophy, 
between patients with and without myocardial ischemia, including an anticipated 
dropout rate of 5%. In total 153 patients were invited to participate after undergoing 




Figure 5. Flow chart of participants included in study 2 and 3  
 
 
8.1.3 Study 3  
 
Study 3 is a post-hoc analysis from the MicroCAD study. We excluded two 
participants with intracoronary stents, and five participants were excluded because of 
insufficient CCTA image quality for quantitative analysis, leaving 125 patients 
eligible for study 3 (Figure 5).  
8.2 Cardiac imaging 
8.2.1 Transthoracic echocardiography 
 
All patients were examined with transthoracic echocardiography following a 
standardized protocol using Siemens Acuson Sequoia C512 ultrasound scanner 
(Siemens, Mountain View, CA, USA) in study 1 and by using a Phillips iE33 
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ultrasound scanner (Philips Healthcare, Best, the Netherlands) in study 2 and 3. 
Echocardiographic chamber dimensions, left ventricular structure and function were 
assessed as recommended by the contemporary European guidelines at the time of 
study inclusion (88, 89). All echocardiographic images were digitally stored and 
transferred to the Echocardiography Core Laboratory at the University of Bergen. All 
images were analyzed using an offline digital workstation (TomTec Imaging Systems 
GmbH, Unterschleissheim, Germany) blinded to clinical and demographic data by the 
same experienced reader (MTL).  
 Left ventricular dimensions were measured in the parasternal long-axis view. 
Left ventricular volumes and ejection fraction were calculated by Simpson’s biplane 
method. Relative wall thickness was calculated as posterior wall thickness/left 
ventricular internal radius ratio, and considered increased if ≥ 0.43 (89). Left 
ventricular mass was calculated by Devereux’s necropsy validated equation and 
indexed for height2.7(89-91). Left ventricular hypertrophy was considered present if 
left ventricular mass index exceeded 46.7 g/m2.7 in women and 49.2 m2.7 in men (81, 
92). Left ventricular geometry was classified into four patterns by combining relative 
wall thickness and left ventricular mass index as recommended by current guidelines 
(89) (Figure 6).  




8.2.2 Myocardial contrast echocardiography 
 
 Myocardial contrast echocardiography uses contrast agents to evaluate 
myocardial perfusion (49). The contrast agents consist of gas-filled microbubbles of 
the same size as the red blood cells, and the microbubbles therefore remain within the 
vascular bed. At low-frequency ultrasound, the microbubbles oscillate, allowing 
visualization, while a flash of high-frequency ultrasound will destroy the 
microbubbles. The rate of microbubble replenishment after destruction reflects the 
myocardial perfusion. At rest, the contrast fills within five heart-beats after flash 
when myocardial perfusion is normal. If the contrast replenishment occurs later than 
five heart-beats, this reflects hypoperfusion, which is indicative of myocardial 
ischemia at rest. During exercise or pharmacological stress, myocardial blood flow 
increases in order to meet the increased oxygen demand of the left ventricle. Thus, 
during stress, it is expected that the microvasculature is re-filled faster, within two 
heart-beats after microbubble destruction. Reduced myocardial perfusion at peak 
stress is indicative of stress-induced myocardial ischemia. Myocardial contrast 
echocardiography was performed by the same experienced operator (MTL) in all 
studies.  
 In study 1, myocardial contrast echocardiography was performed at rest before 
the scheduled coronary angiography. Real-time, low-mechanical index and 
destruction-replenishment myocardial contrast echocardiography was performed 
using Cadance Contrast Pulse Sequencing technology (Acuson Sequoia C512 
echocardiograph, Siemens, Mountain View, CA, USA) (93). All participants were 
given an intravenous bolus injection of 0.3 ml perflutren lipid microsphere ultrasound 
contrast (Luminity ®, Lantheus Medical Imaging, North Billerica, MA, USA) before 
perfusion imaging. To ensure a stable contrast concentration, bolus dosages were 
given repeatedly if necessary. Myocardial perfusion was visually scored as normal 
(contrast replenishment within five heart-beats after flash) or ischemic (contrast 
replenishment occurring later than five heart-beats after flash) in each left ventricular 
segment using apical 2-, 3- and 4- chamber views and the 17-segment model of the 
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left ventricle (93). The extent of myocardial ischemia was taken as the number of left 
ventricular segments with ischemia. Severe myocardial ischemia was considered 
present when ≥ 6 left ventricular segments had ischemia.  
 In study 2 and 3, myocardial contrast stress echocardiography was performed 
in all participants after CCTA. The median time from CCTA to myocardial contrast 
echocardiography was 133 days (interquartile range 98-188 days). All participants 
were examined with real-time, low-mechanical index imaging and destruction 
replenishment myocardial contrast stress echocardiography following European 
guidelines (93). Ultrasound contrast (SonoVue, Bracco, Milan, Italy) was given 
intravenously. First, a 1 ml bolus injection was given, followed by 1 ml/h infusion 
using a rotating infusion pump (VueJet, Bracco, Milan, Italy). Myocardial perfusion 
was visually scored as normal or ischemic in all 17-segments of the left ventricle, 
using apical 2-, 3- and 4-chamber views at rest and at peak dobutamine stress, defined 
as 85% of maximum age-predicted heart rate (200 – age) (93). Stress-induced 
myocardial ischemia was considered present when contrast replenishment was 
delayed at peak stress (contrast replenishment occurred after two heart-beats after 
flash) in any left ventricular segment (Figure 7). The extent of myocardial ischemia 
was taken as the number of left ventricular segments with delayed contrast 
replenishment at peak stress.  
Figure 7. Myocardial contrast echocardiography   
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8.2.3 Quantitative coronary angiography 
In study 1, quantitative coronary angiography analysis was performed offline by a 
single reader (IE) blinded to clinical and echocardiographic data using dedicated, 
validated software (QAngio XA 7.1, MEDIS Medical Imaging Systems, Leiden, the 
Netherlands) (94). The coronary arteries were divided into 17 segments, following 
the modified American Heart Association Model (95). The tip of the catheter was 
used for calibration. Plaque area and stenosis severity defined as lumen diameter 
reduction were determined in all coronary segments with lumen diameter >1.5 mm 
(Figure 8).  
Figure 8. Angiographic quantification of coronary artery plaque burden 
and tortuosity  
 
The total plaque burden was defined as the global coronary plaque area. Global 
coronary artery plaque area was calculated as the sum of plaque areas in all coronary 
artery segments in the individual patient. A lumen diameter reduction of ≥ 50% 
compared with a normal proximal segment was considered a significant stenosis. 
Coronary artery tortuosity was assessed in the three main arteries in standardized 
views. The left anterior descending artery was assessed in the right anterior oblique 
view with cranial angulation, the left circumflex artery in the left anterior oblique 
view with caudal angulation and the right coronary artery in the right anterior oblique 
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view (71). Coronary artery tortuosity was regarded present if ≥ 3 curves >45° were 
found in the same artery during systole and diastole (Figure 8) (71).  
8.2.4 Coronary computed tomography angiography 
Coronary computed tomography angiography acquisition  
CCTA images were obtained by a 2x128-slice dual source computed tomography 
(CT) scanner (Somatom Definition Flash, Siemens, Germany) with ECG-gated 
acquisitions following recommended guidelines (96). Patients with heart rate > 60 
beats per minute were given metoprolol intravenously (1 mg/ml, maximum 20 mg) 
until heart rate was ≤60 beats per minute. A non-contrast enhanced scan was first 
performed to determine coronary calcium score following the Agatston method. The 
patients then received non-ionic contrast given as intravenous infusion, in total 80-
115 ml iomeprol 400 mg I/ml (Iomeron®, Bracco, Milan, Italy) according to body 
weight. All patients received 0.4 mg nitroglycerin sublingual prior to CCTA in order 
to increase image quality. Experienced readers analyzed the images for detection of 
coronary artery stenosis using a modified 20-segment American Heart Association 
model (95, 97). Non-obstructive CAD was defined as presence of ≥ one stenosis with 
lumen diameter reduction 1-49% in any coronary artery segment.  
Quantitative coronary plaque analysis  
CCTA images were anonymized before quantitative coronary plaque analysis by a 
single reader (IE) blinded to clinical and echocardiographic data. The coronary 
segments were defined according to the 17-segment model of the Society of 
Cardiovascular Computed Tomography (97). Quantitative plaque analysis was 
performed in the left main stem, the left anterior descending coronary artery, the left 
circumflex artery and the right coronary artery with lumen diameter >2.0 mm using a 
validated software tool (QAngio CT Research Edition version 3.1.4.2, Medis medical 
imaging systems, Leiden, The Netherlands) (Figure 9) (69, 70). The outer and inner 
walls of the coronary arteries were detected automatically, and manually adjusted 
when needed. The total plaque burden was defined as the total plaque volume in the 
individual patient. The total plaque volume was calculated by subtracting the lumen 
volume from the outer vessel wall volume. Plaque composition was automatically 
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defined according to the radio density in Hounsfield units, with scan-specific 
thresholds adapted to lumen contrast intensity (98). Plaque composition was defined 
as low-attenuation, fibrous-fatty, fibrous or dense calcium (98). Non-calcified plaque 
volume was defined as the sum of low-attenuation, fibrous-fatty and fibrous plaque 
volumes. Segment involvement score was calculated as the total number of segments 
with plaque (range 0-17) (9). 
Figure 9. Quantification of coronary artery plaque burden by coronary 
computed tomography angiography  
  
8.3 Ethics 
All studies were performed in accordance with the 1975 Declaration of Helsinki and 
the Norwegian Health Research Act (99). The study protocols were approved by the 
Regional Committee for Medical and Health Research Ethics, with reference number 
237.07 for study 1 and 2012/2167 for study 2 and 3. Study 1 is registered with 
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identifier NCT01122069 and study 2 and 3 with identifier NCT01853527 at 
www.clinicaltrials.gov. All participants gave written informed consent before study 
inclusion. In all studies, the recommendations for the conduct, reporting, editing, and 
publication of scholarly work in medical journals from the International Committee 
of Medical Journal Editors were followed (100). Inter-observer analysis in Study 3 
was approved by the Data Protection Official at Haukeland University Hospital and 
by the Regional Committee for Medical and Health Research Ethics.  
8.4 Cardiovascular risk factors  
Blood pressure was measured in accordance with the European guidelines on 
management of hypertension which were current at the time of study inclusion (101, 
102). In study 1, a manual sphygmomanometer was used, while automatic 
measurements with an Omron M4 apparatus (Omron Healthcare Co, Hoofddorp, the 
Netherlands) were taken in study 2 and 3. Three measurements of brachial blood 
pressure were taken in the seated position with one-minute intervals after five 
minutes rest. Office blood pressure was taken as the average of the last two 
measurements. Office hypertension was defined as systolic blood pressure ≥140 
mmHg and/or diastolic blood pressure ≥90 mmHg (101, 102). In all studies, 
hypertension was considered present if the participant had history of hypertension, 
used antihypertensive medication or had office hypertension. Medical history, 
smoking habits and use of medication were self-reported in standardized 
questionnaires. In study 1, the results from blood tests were collected from the 
medical journals. In study 2 and 3, fasting blood samples were collected for analyses 
of serum lipid profile, hemoglobin A1c (HbA1c) and creatinine. Glomerular filtration 
rate was calculated using the Chronic Kidney Disease Epidemiology Collaboration 
formula (103). Hypercholesterolemia was defined as total cholesterol > 6.5 mmol/L 
or use of lipid-lowering treatment in the individual patient. Diabetes was defined as 
history of diabetes in study 1. In study 2 and 3, diabetes was defined as history of 
diabetes and/or HbA1c ≥ 48 mmol/mol (104).  
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8.5 Statistics  
Statistical analyses were performed using Statistical Package for Social Sciences 
version 20.0- 25.0 (IBM Corporation, Armonk, NY, USA) and GraphPad Prism 
version 8.0.1 (GraphPad Software, San Diego, California, USA). Continuous 
variables with normal distribution were presented as mean ± standard deviation and 
non-normally distributed variables (calcium score, calcified plaque) as median and 
interquartile range. Categorical variables were presented as numbers and percentages.   
  In study 1, the participants were grouped according to sex. In study 2 and 3, 
the participants were grouped according to the presence of myocardial ischemia. The 
groups were compared using the independent sample t-test for continuous variables 
with normal distribution, Mann-Whitney U test for continuous variables with non-
normal distribution, and Chi-square test for categorical variables. 
  Univariable associations were tested in univariable logistic and linear 
regression analyses. Variables were entered into the multivariable linear and logistic 
regression models, where variables with p<0.10 in univariable regression or 
important clinical value were selected. Collinearity tools were used in multivariable 
linear regression, and reported as variance inflation factor and tolerance in study 1. 
Results from logistic regression were reported as odds ratio (OR) with 95% 
confidence interval (CI). Results from linear regression were reported as standardized 
beta coefficient (β) for individual variables and multiple R2 for multivariable models. 
Receiver operating characteristic curves were plotted to test the association of total 
plaque burden with severe myocardial ischemia in study 1 and presence of 
myocardial ischemia in study 3. Chi-square test of trends was used to compare 
frequency of myocardial ischemia across quartiles of different measurements of 
coronary artery plaque burden (total plaque volume, non-calcified plaque volume, 
calcified plaque volume, coronary calcium score) in study 3.  
 Intra- and inter-observer reliabilities were reported as intraclass correlation 
coefficient with 95% CI. In study 1, intra-observer reliability of plaque area 
measurements and myocardial perfusion assessment were calculated from 
angiographic and echocardiographic images of 11 randomly selected participants 
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analyzed twice by the same reader (IE for plaque area and MTL for myocardial 
perfusion). In study 3, intra-observer reliability of the total plaque volume was 
calculated from comparison of assessment of the total plaque burden analyzed twice 
by the same reader (IE) from 10 randomly selected participants. Inter-observer 
reliability was calculated from comparison of assessment of the total plaque volume 
by two independent readers (IE and JS) in 20 randomly selected participants.  
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9. Summary of results 
9.1 Study 1  
The aim of this study was to assess if global coronary artery plaque area and 
tortuosity were associated with myocardial ischemia in patients with NSTEMI. In the 
108 patients with NSTEMI, 31% were women and the mean age was 67±12 years. 
The proportion of patients with age >65 years was higher in women (71% vs. 50%, 
p=0.045), while mean age and serum troponin T levels did not differ between women 
and men. Hypertension was found in 44% of patients, hypercholesterolemia in 49%, 
diabetes in 19%, and 28% were current smokers.  
 The extent of myocardial ischemia was similar in women and men, reflecting a 
comparable average myocardial infarction size in the left ventricle (6.9 ±3.7 vs. 
7.2±3.4 left ventricular segments, p=0.747). In total 1252 segments (88% of visible 
segments) were used for assessment of coronary plaque area. Intra-observer 
reliability of global coronary artery plaque area measurements and myocardial 
perfusion was good, with intraclass correlation coefficient 0.86 (95% CI 0.75-0.91) 
and 0.95 (95% CI 0.90-0.98), respectively. Global coronary artery plaque area did not 
differ significantly between women and men (35±22 mm2 vs. 43±21 mm2, p=0.071), 
in spite of women having lower prevalence of significant stenosis (74% vs. 91%, 
p=0.021). Global coronary plaque area (per 10 mm2) was associated with severity 
(OR 1.32, [95% CI 1.05-1.66], p=0.019) and extent of myocardial ischemia in 
univariable analysis (β 0.27, p=0.005). A 10 mm2 higher plaque area was associated 
with presence of severe ischemia (OR 1.35, [95% CI 1.01-1.80], p=0.047) in 
multivariable analysis after adjusting for presence of significant stenosis and 
cardiovascular risk factors (Figure 10). In multivariable linear regression analysis, the 
association of larger global coronary artery plaque area with larger extent of ischemia 
was attenuated after adjusting for presence of significant stenosis and cardiovascular 
risk factors (β 0.18, p=0.057). 
 In total, 273 native main coronary arteries were visualized. Due to low image 
quality, 34 were excluded, leaving 239 (88%) included for analysis of coronary 
 35 
tortuosity. Tortuosity was found in 82% of women and 61% of men (p=0.026). 
Coronary artery tortuosity was not associated with presence of severe myocardial 
ischemia in univariable or multivariable logistic regression analysis (OR 0.50, [95% 
CI 0.27-1.21], p=0.123 and OR 0.49, [95% CI 0.17-1.37], p=0.173, respectively). 
Tortuosity was not associated with extent of myocardial ischemia in univariable or 
multivariable linear regression analysis (β -0.16, p=0.094 and β -0.12, p=0.191, 
respectively) 
Figure 10. Determinants of severe myocardial ischemia (≥6 left ventricular 
segments) in multivariable logistic regression analysis  
 
9.2 Study 2 
The aim of this study was to assess the association between left ventricular 
hypertrophy and myocardial ischemia in symptomatic patients with non-obstructive 
CAD by CCTA. In the total study population, mean age was 63±8 years, and 56% 
were female. The patients were divided in two groups according to presence or 
absence of myocardial ischemia. Myocardial ischemia was identified as presence of 
stress-induced myocardial ischemia in any left ventricular segment. Myocardial 
ischemia was found in 69 patients (52%). Hypertension was found in 81% of patients 
with myocardial ischemia and in 68% of those without (p=0.077). Obesity was found 
in 16% of patients with myocardial ischemia and in 32% of those without (p=0.032). 
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Diabetes was found in 13%, smoking in 16% and hypercholesterolemia in 48% of the 
total study population, and comparably in groups with and without myocardial 
ischemia. Left ventricular mass index was higher and left ventricular hypertrophy was 
more prevalent in patients with myocardial ischemia compared to patients without 
myocardial ischemia (Figure 11). The calcium score and segment involvement score 
were similar in the two groups. 
Figure 11. Left ventricular mass index and presence of left ventricular 
hypertrophy in groups with and without myocardial ischemia  
 
In multivariable logistic regression analysis, left ventricular hypertrophy was 
independently associated with myocardial ischemia (OR 3.19, [95% CI 1.04-9.76], 
p=0.043) after adjusting for age, hypertension, obesity, hypercholesterolemia, 
calcium score and segment involvement score. In univariable linear regression 
analyses, larger extent of myocardial ischemia was associated with presence of left 
ventricular hypertrophy (β 0.19, p=0.034), hypertension (β 0.20, p=0.021) and 
hypercholesterolemia (β 0.18, p=0.039). Left ventricular hypertrophy remained 
associated with larger extent of myocardial ischemia (β 0.23, p=0.010) after adjusting 
for age, hypertension, obesity, hypercholesterolemia, calcium score, and segment 
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involvement score in multivariable linear regression analysis (multiple R2 = 0.18, 
p=0.001).  
9.3 Study 3  
The aim of this study was to assess the association between total coronary artery 
plaque burden by CCTA and myocardial ischemia in symptomatic patients with non-
obstructive CAD. The mean age was 62±9 years in the study population, and 58% 
were women. The 125 participants were grouped according to presence or absence of 
myocardial ischemia. Myocardial ischemia was found in 66 participants. The groups 
with and without myocardial ischemia did not differ in age, prevalence of female sex, 
hypertension and diabetes (all p>0.05). The total plaque volume and non-calcified 
plaque volume were higher in participants with myocardial ischemia (Figure 12). 
Calcified plaque volume and coronary calcium score did not differ between the 
groups (both p>0.05).  
Figure 12. Total coronary artery plaque volume and non-calcified plaque 
volume in patients with and without myocardial ischemia  
 
  
 The prevalence of myocardial ischemia increased with increasing quartiles of 
total plaque volume and non-calcified plaque volume. No associations were found 
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between quartiles of calcified plaque, calcium score and prevalence of myocardial 
ischemia. Left ventricular mass index was associated with myocardial ischemia in 
univariable regression analysis (OR 1.06, [95% CI 1.02 – 1.11], p = 0.006), while no 
significant associations were found between age, female sex, hypertension, diabetes 
and myocardial ischemia (all p>0.05). A higher total plaque volume and total non-
calcified plaque volume tended to be associated with presence of myocardial 
ischemia in univariable analyses ((OR 1.02, [95% CI 1.01 – 1.03]) and (OR 1.02, 
[95% CI 1.01 – 1.03]), respectively, both p=0.052). No significant associations 
between total calcified plaque volume, calcium score or segment involvement score 
with presence of myocardial ischemia were found in univariable analyses (all 
p>0.05). 
 In multivariable logistic regression analysis, 10 mm3 increase in total plaque 
volume (OR 1.02, [95% CI 1.00 – 1.04], p = 0.044) and left ventricular mass index 
(OR 1.06, [95% CI 1.01 – 1.11], p = 0.016) were both independently associated with 
myocardial ischemia after adjusting for age, female sex, hypertension, diabetes and 
calcium score (all p>0.05). The association between non-calcified plaque volume and 
myocardial ischemia remained non-significant in a multivariable logistic regression 





The current PhD project studied the associations between coronary artery plaque 
burden and coronary tortuosity assessed by invasive coronary angiography with 
resting myocardial ischemia in NSTEMI, and the associations between left 
ventricular hypertrophy and coronary artery plaque burden with stress-induced 
myocardial ischemia in symptomatic patients with non-obstructive CAD. The results 
from this PhD project have added to current knowledge in several aspects. First, in 
NSTEMI patients, higher total coronary artery plaque area was associated with severe 
myocardial ischemia independent of presence of significant coronary artery stenosis, 
while coronary artery tortuosity did not impact myocardial perfusion. Second, in 
symptomatic patients with non-obstructive CAD, left ventricular hypertrophy was 
associated with presence of myocardial ischemia. Third, higher total coronary 
atherosclerotic plaque volume was associated with presence of myocardial ischemia, 
independent of left ventricular mass, in symptomatic patients with non-obstructive 
CAD. Taken together, our findings imply the importance of integrating structural and 
functional imaging of patients with ischemic heart disease.  
10.1 Clinical importance of myocardial ischemia in non-
obstructive coronary artery disease  
Our key findings emphasize that anatomically non-obstructive CAD does not 
rule-out presence of myocardial ischemia. In study 1, all patients had evidence of 
myocardial ischemia by myocardial contrast echocardiography regardless of presence 
of obstructive stenosis by coronary angiography. In study 2 and 3, myocardial 
ischemia was found in around half of the participants with symptomatic non-
obstructive CAD by CCTA. Accordingly, our results emphasize that patients with 
non-obstructive CAD need ischemia testing in order to be categorized into groups 
with and without myocardial ischemia.  
 The prognostic impact of objective evidence of myocardial ischemia in 
patients with non-obstructive CAD and stable symptoms suggestive of ischemic heart 
disease has been demonstrated (5-7). In 2000, Buchtal et al. found that seven of 35 
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symptomatic women (20%) with normal angiography (≤20% stenosis) had metabolic 
evidence of myocardial ischemia assessed by magnetic resonance spectroscopy 
during handgrip exercise (105). Johnson et al. expanded the importance of these 
findings by demonstrating that metabolic evidence of myocardial ischemia predicted 
cardiovascular outcome during three years follow-up, with hospitalization for 
unstable angina and repeated angiography as the most common events (5). Further, 
Schindler et al. investigated myocardial blood flow using positron emission 
tomography during sympathetic stimulation with a cold pressor test in 72 
symptomatic patients with normal coronary arteries by coronary angiography (6). 
Abnormal myocardial blood flow was found in 69% of patients, and the group with 
abnormal myocardial blood flow had higher incidence of cardiovascular events 
during five years follow-up. However, the association between abnormal myocardial 
blood flow and incidence of cardiovascular events was attenuated after adjusting for 
cardiovascular risk factors, pointing to the importance of cardiovascular risk factors 
also in absence of obstructive CAD (6). In a study including 100 symptomatic women 
with normal coronary arteries or non-obstructive CAD by coronary angiography, 
global magnetic resonance myocardial perfusion imaging predicted adverse 
cardiovascular events (7). Taken together, in symptomatic patients with non-
obstructive CAD, the presence of myocardial ischemia is likely to imply a worse 
prognosis. In the light of the current literature, our results demonstrated that 
myocardial ischemia was found in around half of symptomatic patients with non-
obstructive CAD by CCTA, thus identifying a subgroup which is likely to have an 
impaired prognosis.  
10.2 Total plaque burden and myocardial ischemia  
Our results showed that the total plaque burden estimated from coronary angiography 
was associated with severe myocardial ischemia in NSTEMI patients, independent of 
presence of significant stenosis. In addition, we demonstrated that the total plaque 
burden was independently associated with myocardial ischemia in symptomatic 
patients with non-obstructive CAD by CCTA. 
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 Previous studies of the association of the total plaque burden quantified from 
CCTA and myocardial ischemia have yielded somewhat diverging results (68, 106-
108). Bakhshi et al. tested whether plaque features from quantitative CCTA were 
associated with myocardial ischemia independent of coronary artery stenosis lumen 
reducing severity in 365 patients with suspected or known CAD and clinical referral 
to coronary angiography (106). The patients underwent CCTA, myocardial CT 
perfusion imaging and single photon emission computed tomography (SPECT). All 
analyses were done on a vessel level, where plaque features from coronary arteries 
were matched with the corresponding myocardial perfusion territory by SPECT and 
myocardial CT perfusion. With SPECT as the reference of myocardial ischemia, 
percentage plaque volume was independently associated with myocardial ischemia in 
multivariable analysis, in addition to maximum percentage stenosis and subjective 
“vulnerable” plaque features. However, maximum percent diameter stenosis was the 
only independent variable in multivariable regression analysis predicting myocardial 
ischemia by CT perfusion imaging. Accordingly, their results from SPECT are in line 
with our findings, but it is difficult to draw any strong conclusions from their study. 
 Further, non-calcified plaque has been suggested to cause myocardial ischemia 
independent of stenosis severity (68, 107, 108). Diaz-Zamudio et al. showed that the 
low-density, non-calcified plaque burden, was associated with myocardial ischemia 
by SPECT, independent of stenosis severity (107). Of note, they included only 
patients with single-vessel disease. Moreover, Driessen et al. showed that non-
calcified plaque burden estimated from CCTA was associated with reduced fractional 
flow reserve and reduced myocardial blood flow by positron emission tomography, 
independent of stenosis severity (68). Gaur et al. evaluated whether plaque 
characteristics by CCTA and CT-derived fractional flow reserve were associated with 
hemodynamically significant stenosis, taken as invasive fractional flow reserve 
≤0.80, in symptomatic patients with clinically indicated coronary angiography (108). 
They showed that inclusion of low-density, non-calcified plaque burden and CT-
derived fractional flow reserve ≤ 0.80 improved lesion-specific prediction of 
myocardial ischemia over stenosis severity alone (108). However, these studies did 
not include the total plaque burden in multivariable analyses due to collinearity with 
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the non-calcified plaque, limiting direct comparison with our findings (68, 107, 108). 
 Less is known about the association between the total plaque burden and 
myocardial ischemia in non-obstructive CAD (21). Schuijf et al. grouped 381 patients 
according to the presence of normal, non-obstructive CAD or obstructive CAD by 
CCTA in a sub-study using the same study population as Bakhshi et al. (21, 106). In 
line with our results, the total atherosclerotic plaque burden was higher in patients 
with non-obstructive CAD and myocardial ischemia by CT perfusion or SPECT than 
in those with normal perfusion (21). However, our findings expand their results by 
demonstrating that the relationship between increasing plaque burden and myocardial 
ischemia was independent of confounders, including cardiovascular risk factors, 
calcium score and left ventricular mass.  
  Moreover, it may be suggested that the relationship we found between 
increasing plaque burden and ischemia could contribute to explain the beneficial 
effect of statin treatment seen in several observational studies of non-obstructive 
CAD (44, 109). In fact, in an analysis of clinically indicated serial CCTA, statin 
treatment was associated with slower progression of the total plaque volume together 
with an increase in plaque calcification (110).  
 Taken together, our results demonstrate that the total plaque burden, defined as 
both calcified and non-calcified plaque, was associated with myocardial ischemia in 
non-obstructive CAD. Integrating our results with the current literature, 
quantification of the total plaque burden by CCTA may provide improvement of non-
invasive prediction of myocardial ischemia. Further studies should test whether the 
association between the total plaque burden and myocardial ischemia in non-
obstructive CAD is related to reduced coronary blood flow (56, 57) or microvascular 
dysfunction (58). 
10.3 Left ventricular hypertrophy and myocardial ischemia  
In study 2, we showed that left ventricular hypertrophy was associated with 
myocardial ischemia in symptomatic patients with non-obstructive CAD by CCTA.  
The association between left ventricular hypertrophy and myocardial ischemia has 
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been shown before, although in other study populations (111-113). In 1990, Salcedo 
et al. showed that left ventricular mass predicted ischemia by SPECT, independently 
of angiographic significant stenosis in stable patients referred to coronary 
angiography (111). More recently, in a study of 33 hypertensive patients without 
CAD, Olsen et al. found that echocardiographic left ventricular hypertrophy was 
associated with impaired myocardial blood flow at pharmacological stress assessed 
by dipyridamole positron emission tomography (112). Myocardial ischemia due to 
left ventricular hypertrophy has been suggested as the explanation for angina 
symptoms in patients with aortic stenosis and absence of CAD (113). Ahn et al. 
included patients with severe aortic stenosis without obstructive CAD at coronary 
angiography and assessed myocardial perfusion by adenosine-stress cardiac magnetic 
resonance imaging (113). Patients with angina had higher left ventricular mass and 
lower myocardial perfusion reserve than those without angina. In addition, left 
ventricular mass was the strongest contributor to reduced myocardial perfusion in 
multivariable analysis (113). Besides, animal studies have demonstrated that left 
ventricular hypertrophy may lower the ischemic threshold by increasing the oxygen 
demand, reducing the capillary density and increasing interstitial fibrosis in the 
myocardium (22, 114, 115). The concordance of our findings with previous studies 
supports that left ventricular hypertrophy may contribute to myocardial ischemia in 
the absence of obstructive CAD.  
 Accordingly, our results emphasize the importance of maintaining normal 
blood pressure in non-obstructive CAD. Hypertension is both a cause of left 
ventricular hypertrophy and a risk factor for development of CAD (24, 74, 116). 
Together, this may lower the threshold for development of myocardial ischemia. It 
has been demonstrated that hypertension is independently associated with increased 
risk of cardiovascular events in patients with non-obstructive CAD by CCTA, after 
adjusting for diabetes and the extent of non-obstructive CAD, taken as segment 
involvement score (66). Importantly, left ventricular hypertrophy increases the risk of 
death, independent of the presence of obstructive CAD by coronary angiography 
(117, 118). Our results suggest that regression of left ventricular hypertrophy should 
be a treatment target in non-obstructive CAD. Clinical trials show that reduction of 
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left ventricular mass and normalization of left ventricular geometry improve 
prognosis of hypertensive subjects with electrocardiographic left ventricular 
hypertrophy (80, 119). Further, in the observational Campania Salute network, blood 
pressure lowering through antihypertensive treatment, and weight loss led to a 
reduction of left ventricular mass, expanding the results from clinical trials (23, 120). 
Moreover, the Copenhagen City Heart Study demonstrated that increased levels of 
self-reported physical activity were associated with improved outcome, independent 
of presence of echocardiographic left ventricular hypertrophy (121). Taken together, 
our results and the current literature from hypertensive and community-based studies 
suggest that life-style interventions and hypertensive treatment may contribute to 
improve prognosis also in patients with non-obstructive CAD when left ventricular 
hypertrophy is present. This hypothesis should be tested in prospective studies.  
10.4 Coronary artery tortuosity and myocardial ischemia  
In study 1, we did not find any significant relationship between the severity or extent 
of myocardial ischemia and coronary artery tortuosity. Tortuosity was more prevalent 
in women, in line with other studies (72, 73). The body of evidence regarding 
whether coronary artery tortuosity impacts myocardial perfusion in humans is limited 
(61). In a study including 96 patients with stable chest pain and normal or near-
normal coronary arteries (<30% stenosis on coronary angiography), coronary artery 
tortuosity was found in 35% of patients with myocardial ischemia by myocardial 
contrast stress echocardiography and in 5% of those with normal myocardial 
perfusion (61). Direct comparison with our findings should be made with caution. 
First, we used a less strict definition of coronary tortuosity, which may explain the 
higher prevalence of coronary tortuosity in our study. Second, we studied patients 
with NSTEMI while Gaibazzi et al. studied patients with stable disease. It is likely 
that the disease mechanisms underlying myocardial ischemia differ between these 
patient populations. Third, Gaibazzi et al. did not report whether coronary tortuosity 
was independently associated with myocardial ischemia in multivariable analysis, 
which further limits the ability to compare our findings (61).  
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10.5 Sex differences in non-obstructive coronary artery 
disease  
There are sex-differences in ischemic heart disease, both in clinical presentation, 
disease mechanisms, and outcomes (122). In study 1, we found that women less often 
had obstructive CAD, in line with previous studies (8). In fact, the prevalence of 
women is higher in MINOCA than in myocardial infarction with obstructed coronary 
arteries (39, 40). We found that the impact of coronary artery plaque burden and 
tortuosity on myocardial ischemia were similar in women and men. Coronary 
vasospasm and thrombophilia have been suggested to contribute to the higher 
prevalence of women in MINOCA, but the mechanisms explaining sex differences in 
myocardial infarction are not fully understood (48).  
  The definition of non-obstructive CAD is important when addressing sex 
differences. CCTA studies show that women more often have normal coronary 
arteries and less often obstructive CAD (43, 123). The prevalence of women and men 
is similar when non-obstructive CAD is taken as 1-49% coronary artery stenosis (43, 
123). Accordingly, if non-obstructive CAD is defined as the absence of obstruction, 
there will be a predominance of women as they are more likely to have normal 
CCTA. In study 2 and 3, the prevalence of women and men were similar. We did not 
find any difference in the prevalence of myocardial ischemia between women and 
men. In our multivariable models, sex was not associated with myocardial ischemia. 
Our findings did not provide any evidence of sex per se as a determinant of 
myocardial ischemia in non-obstructive CAD. 
  We found that left ventricular hypertrophy and the total plaque burden were 
associated with myocardial ischemia. Previous studies show that left ventricular 
hypertrophy is associated with adverse prognosis in both women and men (82). It has 
also been demonstrated that the extent of CAD, whether non-obstructive or 
obstructive, predicts worse prognosis similarly in women and men (43, 66). In light 
of current knowledge, our findings suggest that left ventricular hypertrophy and the 
coronary plaque burden should be considered as possible determinants of myocardial 
ischemia both in women and men with non-obstructive CAD.  
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10.6 Methodological considerations 
The interpretation of the results presented in this thesis depends on the internal and 
external validity. Internal validity refers to whether one can trust that the results 
obtained in a study are true, while external validity refers to whether the results may 
be generalized to other patients than those included in the studies.   
10.6.1 Internal validity 
The internal validity depends on how the study was conducted, including study 
design and methods used. The risk of selection bias, reflecting a systematic difference 
between study groups, was small in all studies, as the participants were prospectively 
recruited. However, we cannot exclude a referral bias in study 2 and 3, as the 
participants were recruited among patients who had been referred to CCTA by 
cardiologists. Information bias means that there is a systematic difference between 
the groups concerning the collection of information. All clinical and demographic 
data were collected prior to myocardial perfusion imaging and all imaging analysis 
were done blinded, as recommended for clinical trials (124). We adjusted for possible 
confounders affecting the associations between plaque burden, tortuosity and left 
ventricular hypertrophy with myocardial ischemia in multivariable analyses in all 
studies. However, there are other factors that may affect myocardial ischemia that we 
did not assess, such as coronary vasospasm and microvascular function (58). Besides, 
our studies do not provide insights on the specific mechanisms that underlie the 
associations we found. 
Evaluation of coronary plaque burden and tortuosity  
The total plaque burden was estimated from invasive coronary angiograms in study 1. 
Invasive coronary angiography only visualizes the lumen and not the arterial wall. 
Thus, plaque quantification from invasive coronary angiography images represents a 
crude estimation of the amount of plaque based upon the arterial lumen reduction 
alone, since the method is unable to account for atherosclerosis with preserved lumen 
diameter and positive remodeling. Alternative methods to quantify plaque during 
invasive coronary angiography are intravascular ultrasound and optical coherence 
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tomography (125, 126). However, these methods were not consistently used in the 
included study population. 
 Quantitative CCTA is a better method for plaque quantification than invasive 
coronary angiography since the plaque itself is visualized (127). Several aspects of 
CCTA should be noted when interpreting our results. CCTA is not recommended 
when image quality is expected to be low, as for patients with severe obesity or high 
and irregular heart rate (96). In addition, CCTA is often uninterpretable in patients 
with high calcium score, which also increases the probability of obstructive CAD 
(128, 129). Accordingly, patients with high calcium score are often referred to 
invasive coronary angiography rather than proceeding with CCTA. Thus, these 
patients were not eligible for inclusion in study 2 and 3. Quantitative CCTA has good 
agreement of stenosis lumen reducing severity compared to coronary angiography 
(70). Besides, quantitative CCTA has good agreement with the estimation of plaque 
volume and characterization of plaque as calcified or non-calcified by intravascular 
ultrasound (98, 130). Of note, quantitative CCTA is unable to differentiate the normal 
vessel wall from non-calcified plaque volume, and limited ability to differentiate 
between different the types of non-calcified plaque (127, 130). Therefore, we chose 
to present the plaque burden as calcified and non-calcified, without further 
subgrouping. In addition, several fixed thresholds of Hounsfield units have been 
suggested to characterize plaque composition by CCTA (62). Luminal contrast 
density has been shown to affect plaque characterization when using fixed thresholds 
(98, 131). Therefore, we used a method for plaque characterization which adapts the 
thresholds to the luminal contrast density in the specific scan, instead of using fixed 
thresholds (98). There is currently no consensus on how to quantify the total plaque 
burden, for instance with regards to how small arterial size that can be analyzed, and 
whether to include side branches (130).  
  All these factors may limit the ability to compare results across studies 
directly. The protocol for plaque assessment in study 3 was adapted from a research 
center with extensive experience in quantitative CCTA to ensure high quality (127). 
Plaque quantification by CCTA is currently time-consuming, limiting implementation 
in clinical practice. However, the use of machine learning has shown superior 
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performance to that of expert visual assessment of CCTA plaque characteristics 
(132), pointing to the potential of machine learning and artificial intelligence in future 
automated CCTA quantification (133). 
 With regard to coronary tortuosity, there is to date no consensus in the 
definition of coronary tortuosity by coronary angiography (72), so we chose a 
definition used in a previous study (71). The intra-observer reliability for 
measurements of coronary plaque burden in study 1 was good, and in study 3, intra- 
and inter-observer reliability for measurement of the total coronary plaque burden 
were excellent. 
Evaluation of left ventricular mass  
Echocardiography and cardiac magnetic resonance are the best documented methods 
for assessment of left ventricular mass (79). In two-dimensional echocardiography, 
good acoustic windows and accurate quantification of left ventricular dimensions are 
necessary, and the left ventricle is assumed to have a certain geometrical shape (89). 
On the other hand, three-dimensional echocardiography and cardiac magnetic 
resonance imaging can measure cardiac volumes directly, eliminating the need of 
geometrical assumptions (79). However, three-dimensional echocardiography is more 
dependent on image quality, while magnetic resonance imaging is limited by 
increased time to acquire and analyze images, and is less available in clinical practice 
compared to echocardiography (79). Despite the limitations noted, two-dimensional 
echocardiographic assessment of left ventricular mass is recommended in clinical 
practice and the majority of prognostic data are from studies using echocardiographic 
detection of left ventricular hypertrophy (80-82, 89). Several methods are used to 
normalize left ventricular mass to body size, including height and body surface area 
(79, 89). We indexed left ventricular mass to height2.7 and used sex-specific cut-offs, 
because it gives the most accurate estimation of left ventricular mass and the most 
sensitive cut-offs for the detection of left ventricular hypertrophy in both women and 
men, in particular when obesity is present (91, 134). Echocardiographic assessment of 
left ventricular mass was performed following standardized protocols in our 
echocardiography core laboratory, which has contributed to document the prognostic 
value of left ventricular hypertrophy in different patient cohorts and diseases (80, 92). 
 49 
Evaluation of myocardial ischemia by contrast enhanced 
echocardiography   
Myocardial contrast echocardiography is a safe procedure without radiation exposure, 
and provides the evaluation of myocardial perfusion and wall motion, in addition to 
structural assessment (49). Importantly, myocardial contrast echocardiography has 
been shown to have comparable diagnostic performance to SPECT (135) and cardiac 
magnetic resonance perfusion imaging (136), which are alternative methods for 
evaluation of myocardial perfusion. The local expertise and availability led to the 
choice of myocardial contrast echocardiography for evaluation of myocardial 
perfusion in all studies. Cardiac magnetic resonance imaging is currently 
recommended as a part of the diagnostic work-up in MINOCA, as it may not only 
diagnose myocardial ischemia, but also reliably differentiate between myocardial 
infarction and myocarditis (37). However, cardiac magnetic resonance imaging was 
not available at our institution at the time study 1 was performed. The main 
limitations of myocardial contrast echocardiography are the dependence on operator 
expertise and visual assessment of the myocardial perfusion (49). Further, myocardial 
contrast echocardiography does not provide differentiation between myocardial 
ischemia caused by coronary artery stenosis and myocardial ischemia of 
microvascular origin. Finally, the intra-observer reliability of myocardial perfusion in 
study 1 was excellent. 
Statistical considerations  
The main statistical limitations are the cross-sectional study design and small sample 
sizes. The cross-sectional design does not allow the evaluation of causal effects. 
Further, as study 1 and 3 were post-hoc analyses, the probability of type-II errors 
increases as the sample sizes were not calculated with these research questions in 
mind.  
10.6.2 External validity  
In study 1, the patients were prospectively recruited. Thus, the results from study 1 
are likely to be generalizable to other NSTEMI patients. In study 2 and 3, presence of 
at least one cardiovascular risk factor was an inclusion criterion, so the results may 
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not be generalizable to symptomatic patients with non-obstructive CAD and a 
healthier cardiovascular risk factor profile. 
10.7 Clinical implications and future perspectives  
10.7.1 Clinical implications  
Our results have several implications for clinical practice. The results presented in 
this thesis emphasize that non-obstructive CAD by coronary angiography or CCTA 
does not rule out the presence of myocardial ischemia. Accordingly, our results 
underline that patients with non-obstructive CAD by CCTA should undergo further 
ischemia testing to identify patients with chronic myocardial ischemia. Our results 
emphasize that ischemia in non-obstructive CAD may result from reduced oxygen 
supply, increased oxygen demand or a combination. Identification of the contributing 
factors in the individual patient may guide further treatment. While waiting 
randomized trials investigating medical treatment of non-obstructive CAD, our 
findings suggest that the presence of non-obstructive CAD should prompt attention to 
cardiovascular risk factor control in the individual patient through lifestyle-changes 
and medical treatment, in particular antihypertensive therapy.  
10.7.2 Future perspectives   
  There are some aspects in the current definitions of MINOCA and INOCA, 
which should be considered in future research. The current definitions could be 
criticized to be based on expert opinion rather than prognostic evidence (11, 37). 
When reviewing the available literature, it is evident that the term “Ischemia” has 
been used ambiguously in INOCA. It has been used to describe symptoms suggestive 
of myocardial ischemia as well as objective evidence of ischemia (21, 59). This leads 
to different study populations and limited ability to generalize findings. In the 
recently suggested definition of INOCA, objective evidence of ischemia is mandatory 
(11). However, studies using coronary angiography or CCTA have demonstrated 
adverse prognosis in non-obstructive CAD without evaluation of myocardial 
ischemia (33, 45, 46). Thus, there is a need to further clarify the prognostic 
implications of objective evidence of ischemia in non-obstructive CAD.  
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 Further, in the current definitions of MINOCA and INOCA, patients with 
normal coronary arteries (0% stenosis) and non-obstructive CAD defined as 1-49% 
stenosis are not separated (11, 37). Several CCTA studies have demonstrated that the 
prognosis in patients with non-obstructive CAD is worse than for those with normal 
coronary arteries, pointing to the importance of separating these two groups (9, 45, 
137). On the other hand, few studies have compared outcome according to presence 
of normal coronary arteries or non-obstructive CAD in MINOCA, as pointed out by 
the European Society of Cardiology (37, 40). However, most patients with normal 
coronary arteries by coronary angiography have evidence of atherosclerosis when 
they are examined with intravascular ultrasound, so further studies are needed to 
evaluate whether such a distinction is fruitful in MINOCA (138). Standardized 
criteria for diagnosing microvascular angina and vasospastic angina have been 
proposed from the Coronary Vasomotor Disorders International Study Group (139, 
140). Taken together, implementation of standardized and precise diagnostic criteria 
is needed to develop evidence-based care for patients with non-obstructive CAD. 
 The results presented in this thesis raises novel hypotheses to be tested in 
future research. Our findings suggest that improved phenotyping of patients with non-
obstructive CAD may be achieved from integrating functional and anatomical 
assessment of determinants of myocardial oxygen supply and demand. 
 The mechanisms underlying the associations we found between left ventricular 
hypertrophy, plaque burden, and ischemia should be further investigated. Whether the 
total plaque burden affects coronary blood flow or is a marker of microvascular 
dysfunction should be explored. In addition, whether the total plaque burden have 
cut-off values with corresponding sensitivity and specificity that may rule-in or rule-
out myocardial ischemia should be tested. Besides, standardized protocols for plaque 
quantification are needed in order to establish cut-off values that can guide clinical 
management. The prospective impact of the total coronary plaque burden estimated 
by quantitative CCTA in non-obstructive CAD should be investigated. 
 The ongoing advancement in non-invasive imaging techniques including 
cardiac magnetic resonance imaging (141, 142), CT perfusion imaging (143) and 
fractional flow reserve derived from CT (144) may shed light on the mechanisms of 
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myocardial ischemia in non-obstructive CAD. However, the optimal diagnostic 
workup and choice of imaging methods for clinical practice requires further studies, 
including evaluation of patient safety and prognostic implications.  
 Our results suggest that studies that aim to develop treatment of non-
obstructive CAD should target the underlying causes of ischemia found in the 
individual patient. Such prospective studies should include evaluation of left 
ventricular hypertrophy and the coronary artery plaque burden, according to our 
findings. In addition, prospective trials should address whether cardiovascular risk 




The key finding in this thesis is that non-obstructive CAD does not rule out 
myocardial ischemia. Our results suggest that the total plaque burden and left 
ventricular hypertrophy may independently contribute to myocardial ischemia in non-
obstructive CAD.  
In study 1, we aimed to determine whether the coronary artery plaque burden and 
tortuosity were associated with myocardial ischemia in NSTEMI patients. We found 
that the coronary artery plaque burden was associated with presence of severe 
ischemia at rest, independent of presence of significant stenosis. No associations were 
found between coronary artery tortuosity and myocardial ischemia.  
In study 2, we aimed to assess the association of left ventricular hypertrophy with 
myocardial ischemia in symptomatic patients with non-obstructive CAD by CCTA. 
We found that left ventricular hypertrophy was independently associated with 
myocardial ischemia in symptomatic patients with non-obstructive CAD.  
In study 3, we aimed to explore the association of the total coronary artery plaque 
burden with myocardial ischemia in symptomatic patients with non-obstructive CAD 
by CCTA. We found that the total coronary artery plaque burden was independently 
associated with presence of myocardial ischemia in symptomatic patients with non-
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Global Coronary Artery Plaque Area is Associated
with Myocardial Hypoperfusion in Women with Non-ST
Elevation Myocardial Infarction
Ingeborg Eskerud, Eva Gerdts, MD, PhD, Jan Erik Nordrehaug, MD, PhD,
and Mai Tone Lønnebakken, MD, PhD
Abstract
Background: Women with non-ST elevation myocardial infarction (NSTEMI) have similar extent of myo-
cardial ischemia but less obstructive coronary artery disease (CAD) than their male counterparts. We tested the
impact of global coronary artery plaque area and artery tortuosity on myocardial perfusion in NSTEMI patients.
Methods: Coronary artery plaque area was determined by quantitative angiography in 108 patients (32%
women) with NSTEMI. Myocardial perfusion was assessed by contrast echocardiography in the 17 individual
left ventricular segments. Artery tortuosity was defined as ‡ 3 curves > 45 in a main coronary artery.
Results: Age, prevalence of hypertension, and diabetes did not differ between sexes (all nonsignificant).
Women had lower prevalence of ‡ 50% coronary artery stenosis (74% vs. 91%, p< 0.05), while global coronary
plaque area (35– 22 vs. 43 – 21mm2) and the number of segments with hypoperfusion (6.9– 3.7 vs. 7.2– 3.4)
did not differ between sexes (both p> 0.07). In multivariate analysis, larger coronary artery plaque area was
associated with a 35% higher risk for having severe myocardial hypoperfusion (odds ratio 1.35 [95% confidence
interval 1.01–1.80], p < 0.05) in the total study population, while no association between artery tortuosity and
myocardial ischemia was found. Similar results were obtained in separate analysis among women and men.
Conclusion: In women and men with NSTEMI, the global coronary artery plaque area was an important
determinant of the severity of myocardial hypoperfusion at rest independent of presence of significant coronary
stenoses. These findings may expand current understanding of NSTEMI in patients with nonobstructive CAD.
Introduction
Sex differences in coronary artery disease (CAD) path-ophysiology have previously been demonstrated both in
autopsy-based and clinical studies,1–3 including differences
in coronary artery plaque composition and distribution as
well as coronary artery tortuosity.4–9 In particular, non-
obstructive CAD on angiography is found more often in
women compared to men, irrespective of clinical presenta-
tion of the coronary artery disease.5
Previous studies using contrast echocardiography or cardiac
magnetic resonance imaging have demonstrated that ischemic
burden measured by these techniques is an important prog-
nosticator in particular in women with nonobstructive
CAD.10,11 In a smaller study,we recently demonstrated that the
extent of myocardial hypoperfusion in patients with non-ST
elevation myocardial infarction (NSTEMI) was comparable in
women and men despite less obstructive CAD in women.7
However, it is not clear whether coronary artery plaque area
may influence myocardial perfusion in NSTEMI patients in-
dependent of presence of significant coronary artery stenoses.
Furthermore, others have suggested that also artery tortuosity
may influence coronary perfusion.9 The aim of this study was
therefore to explore if coronary plaque area and arterial tortu-
osity impacted myocardial perfusion in NSTEMI patients, and
thereby could explain the mismatch between extent of myo-
cardial hypoperfusion and presence of significant CAD previ-
ous reported in NSTEMI women.
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A total of 126 consecutive patients diagnosed with acute
NSTEMI, defined as the combination of chest pain and tro-
ponin T elevation, hospitalized at the Department of Heart
Disease, HaukelandUniversity Hospital, fromMarch through
December 2008 and scheduled for acute coronary angiogra-
phy within 72 hours after admittance were eligible for the
study. Excluding patients with hemodynamically unstable
disease, mechanical valve prostheses or severe pulmonary
disease, a total of 110 patients signed informed consent and all
of them underwent myocardial contrast echocardiography
prior to scheduled coronary angiography.12
For the present post-hoc analysis, reanalyzing the angio-
grams in this previous series with quantitative coronary an-
giography, two of the 110 patients were excluded because all
native coronary arteries were occluded, leaving 108 patients
for the present study population. Clinical risk assessment was
performed in all patients using the thrombolysis in myocar-
dial infarction (TIMI) risk score model.13 The study was
approved by the regional ethical committee and performed in
accordance with the Helsinki declaration.
Quantitative coronary angiography
Quantitative coronary angiography was performed offline
by a single reader (IE) blinded to clinical data and myocardial
perfusion assessment using a digitalized automatic edge de-
tecting analysis software (QAngio XA 7.1, MEDIS Medical
Imaging Systems, Leiden, The Netherlands) (Fig. 1, panel A).
The coronary artery tree was divided into 17 segments,
following the modified American Heart Association model.14
The tip of the catheter was used for calibration. Stenosis
severity and plaque area assessed as lumen diameter reduc-
tion was determined in all vessel segments with a diameter
> 1.5mm. Global coronary artery plaque area was calculated
as the sum of plaque area in all segments. A coronary artery
lumen diameter reduction of ‡ 50 % on the angiogram was
considered a significant stenosis.
Coronary artery tortuosity was measured in the three main
coronary arteries in standardized views: The left anterior
descending artery in the right anterior oblique view with
cranial angulation, the left circumflex artery in the left an-
terior oblique with caudal angulation and the right coronary
artery in the right anterior oblique view.9 Coronary tortuosity
was regarded present if ‡ 3 curves > 45 was found in the
same artery (Fig. 1, panel B).
Echocardiography
Quantitative echocardiography was performed following
the joint European Association of Echocardiography and
American Society of Echocardiography guidelines.15 Left
ventricular (LV) ejection fraction was assessed by the mod-
ified biplane Simpson formula and regional LV function by
wall motion scoring.15 Wall motion score was assessed in
apical 2-, 3-, and 4-chamber views using a 17-segment LV
model as recommended in current quantitation guidelines.15
The average wall motion score value was taken as wall motion
score index in the individual patients. Methods and results
from myocardial contrast echocardiography have previously
been reported in details.7,12 In short, myocardial contrast
echocardiography was performed at rest by real-time low-
mechanical index imaging and destruction–replenishment us-
ing Cadance Contrast Pulse Sequencing technology (Acuson
Sequoia C512, Siemens, Mountain View, CA, echocardio-
graph). An intravenous bolus dosage of 0.3mL Perflutren Li-
pid Microsphere ultrasound contrast (Luminity, Lantheus
Medical Imaging, North Billerica, MA) was given before
perfusion imaging. The bolus dosagewas repeated if necessary
to ensure a stable contrast concentration and avoid contrast
swirling during image acquisition. Regional myocardial per-
fusion was scored visually as normal (contrast replenishment
within five heart beats) or hypoperfusion (delayed contrast
replenishment after more than five heart beats) using the
guideline-recommended 17 segment LV model (Fig. 2).15,16
The extent ofmyocardial perfusion abnormalities was assessed
as the number of segments with hypoperfusion. Severe myo-
cardial hypoperfusionwas considered present if hypoperfusion
was detected in ‡ 6 LV segments.12
Statistics
Data management and statistical analysis were performed
by the IBM SPSS statistical program version 20.0 (IBM
SPSS, Chicago, IL). The study had 80% power to detect a
30% difference in coronary artery stenosis between women
andmen at a statistical level of 0.05. Continuous variables are
reported as mean and standard deviation and categorical
variables as numbers and percentages. Comparisons between
groups were performed by unpaired t-test or chi-squared
FIG. 1. Quantitative coronary
angiography. Coronary artery pla-
que area (A) and coronary artery
tortuosity (B) assessed in the left
anterior descending artery.
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statistics as appropriate. Covariates of global coronary artery
plaque area and tortuosity were identified by Pearson’s cor-
relation coefficient and logistic regression analysis as ap-
propriate. Independent covariates of the extent of myocardial
hypoperfusion were identified in multiple linear regression
analysis. Covariates of severe hypoperfusion (involving ‡ 6
LV segments) were identified in multiple logistic regression
analysis. The associations of presence of severe myocardial
hypoperfusion with global coronary artery plaque area and
presence of significant coronary artery stenosis were tested in
receiver operator characteristics curve analysis. A p value
< 0.05 was considered statistical significant. The intraob-
server variability of myocardial perfusion assessment and of
coronary artery plaque area measurement was calculated
separately from echocardiographic and angiographic images,




The proportion of patients > 65 years of age was signifi-
cantly higher amongwomen, whilemean age, troponinT levels
and TIMI risk score did not differ between women and men
(Table 1). There were no sex differences in anti-ischemic
treatment at study entrance. None of the women were on hor-
mone replacement therapy. The extent of wall motion abnor-
malities and myocardial hypoperfusion did not differ between
women and men, reflecting comparable myocardial infarct size
(Table 2). The mean time between contrast echocardiography
and angiographywas 1.87– 2.6 days, with a median of 1.0 day.
There were no adverse events from contrast infusions, except
for three patients who experienced transient lower back pain.
Coronary artery plaque area
A total of 35 main arteries had proximal total occlusion.
From the total of 1422 coronary artery segments visible on
the angiograms, 69 segments were excluded from analysis
due to poor image quality and vessel overlap, and another 170
segments were excluded due to luminal diameter £ 1.5mm,
which cannot be analyzed with our method, leaving a total of
1252 (88% of visible segments on the angiogram) for as-
sessment of coronary artery plaque area.
Reproducibility of myocardial perfusion score by in-
traclass correlation coefficient was 0.95 (95% confidence
FIG. 2. Myocardial contrast echo-
cardiography. Apical 4-chamber, 2-
chamber and long axis view images
taken five beats post flash demon-
strating subendocardial and trans-
mural hypoperfusion in the apical
left ventricular segments marked
with green arrows.
Table 1. Clinical Characteristics of the Total Study Population and Groups of Women and Men
Total Women Men
(n = 108) (n = 34) (n = 74) p
Age (years) 67 – 12 70 – 12 66– 12 0.160
Age > 65 years (%) 56.5 70.6 50.0 0.045
BMI (kg/m2) 27– 5 27– 5 27 – 4 0.973
Systolic blood pressure (mmHg) 150– 24 150– 22 150 – 25 0.906
Diastolic blood pressure (mmHg) 85 – 13 85 – 13 85– 13 0.917
TIMI risk score 3.24 – 1.41 3.47 – 1.44 3.14 – 1.39 0.252
Family history of premature CAD (%) 40 41 39 0.854
Hypertension (%) 44 44 43 0.932
Hypercholesterolemia (%) 49 65 42 0.028
Diabetes mellitus (%) 19 21 19 0.839
Current smoker (%) 28 15 34 0.040
Peak troponin T level (ng/L) 680– 1170 530– 660 750 – 1300 0.353
Previous myocardial infarction (%) 29 29 29 0.912
Betablocker use (%) 33 32 34 0.884
Calcium channel blockers use (%) 11 9 12 0.608
Statin use (%) 41 32 45 0.229
Acetylsalicylic acid use (%) 42 47 39 0.441
BMI, body mass index; CAD, coronary artery disease; TIMI, thrombolysis in myocardial infarction risk score.
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interval [CI] 0.90–0.98) and for coronary artery plaque area
0.86 (95% CI 0.75–0.91).
Global coronary artery plaque area did not differ signifi-
cantly between women and men despite lower prevalence of
significant coronary artery stenoses and multivessel disease
in women (Table 2). In receiver operating characteristic
curve analysis, global coronary artery plaque area was sig-
nificantly associated with having severe myocardial hypo-
perfusion in both women and men, while presence of
significant coronary artery stenosis was significantly
Table 2. Echocardiographic and Angiographic Findings in the Total Study
Population and Separately in Women and Men
Total Women Men
(n = 108) (n = 34) (n = 74) p
LV end-diastolic diameter (cm) 5.09 – 0.65 4.76 – 0.56 5.25 – 0.65 < 0.001
LV end-systolic diameter (cm) 3.65 – 0.73 3.36 – 0.64 3.79 – 0.73 0.004
Intraventricular septum thickness (cm) 1.20 – 0.18 1.12 – 0.20 1.21 – 0.17 0.737
Posterior wall thickness (cm) 1.02 – 0.13 0.99 – 0.12 1.03 – 0.13 0.140
LV ejection fraction (%) 56 – 12 58 – 12 54– 11 0.165
Extent of wall motion abnormality (segments) 3.6 – 3.7 3.7 – 4.1 3.6 – 3.5 0.893
Extent of hypoperfusion (segments) 7.1 – 3.5 6.9 – 3.7 7.2 – 3.4 0.747
Severe hypoperfusion (%) 63.9 64.7 63.5 0.905
Significant stenosis (%) 85 74 91 0.021
Total coronary artery occlusion (%) 34 35 34 0.878
Wall motion score index 1.22 – 0.23 1.23 – 0.26 1.22 – 0.23 0.880
Multivessel disease (%) 49 35 55 0.052
Coronary artery tortuosity (%) 68 82 61 0.026
Coronary artery plaque area (mm2) 41 – 22 35 – 22 43– 21 0.071
LV, left ventricular.
FIG. 3. Global coronary artery plaque area and severe myocardial hypoperfusion. Receiver operating curve analysis of the
univariate association of presence of severe myocardial hypoperfusion with global coronary plaque area and presence of
significant coronary artery stenosis in women and men.
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associated with severe myocardial hypoperfusion only in
women, probably reflecting the low prevalence of non-
obstructive CAD in men (Fig. 3).
Coronary artery tortuosity
A total of 273 native main coronary arteries were visible on
the coronary angiograms. Of these, 34 were excluded due to
low image quality, leaving 239 (88%) available for analysis of
tortuosity. All three main coronary arteries could be assessed in
65 patients, two in 31 patients, and one in 7 patients. Tortuosity
was more prevalent among women than men (Table 3). Global
coronary artery plaque area did not differ between patients with
tortuous and non-tortuous coronary arteries (42.0– 23.5 vs.
38.0– 17.4mm2, p= 0.367). Tortuosity was not associatedwith
the extent of myocardial hypoperfusion in the total study
population or in men and women analyzed separately.
Determinants of myocardial hypoperfusion
A significant association was found between global coro-
nary plaque area and both severity and extent of myocardial
hypoperfusion in univariate analyses (both p < 0.05) (Tables
3, 4). In multiple logistic regression analysis, adjusting for
known confounders of hypoperfusion, a 10mm2 higher glo-
bal plaque area was associated with a 35% higher risk for
having severe myocardial hypoperfusion on the echocardio-
gram (odds ratio 1.35; 95% CI 1.01–1.80, p = 0.047), inde-
pendent of presence of significant coronary artery stenosis
(Table 3). However, the association of larger global coronary
plaque area with larger extent of myocardial hypoperfusion
was attenuated and became borderline statistically significant
when adjusted for confounders in multivariate analysis
(b= 0.18, p = 0.057) (Table 4).
Discussion
The present study demonstrates that global coronary artery
plaque area is an important determinant of the severity of
myocardial hypoperfusion in NSTEMI patients, indepen-
dent of presence of significant coronary artery stenoses.
Of note, global coronary artery plaque area did not differ
between sexes despite lower prevalence of obstructive CAD
in women. In fact, nonobstructive CAD was nearly 3-fold
more prevalent in women than in men in the present study,
in accordance with previous reports from registries and
meta-analyses.5,6 Although computer tomography coronary
angiography is recognized as a superior method for assess-
ment of coronary artery plaque area, invasive coronary an-
giography is the preferred diagnostic technique for diagnosis
of CAD in current management guidelines for NSTEMI pa-
tients.17 Therefore, our findings are relevant for clinical practice.
Distinct sex differences in coronary atherosclerosis are
well described.2 Typically, women have more diffuse ath-
erosclerosis, smaller arteries and more microvascular in-
volvement.2,18 These factors may contribute to the reported
sex difference in treatment procedures and outcome among
CAD patients.19,20 Intravascular ultrasound in women with
Table 3. Predictors of Severe Myocardial Hypoperfusion ( ‡ 6 LV Myocardial Segments)
Identified in Univariate and Multivariate Logistic Regression Analyses
Univariate analysis Multivariate analysis
Independent variable OR 95% CI p OR 95% CI p
Global coronary plaque area (per 10mm2) 1.32 (1.05–1.66) 0.019 1.35 (1.01–1.80) 0.047
Significant stenosis 5.03 (1.60–15.83) 0.006 5.14 (1.29–20.54) 0.021
Age > 65 years 3.82 (1.67–8.73) 0.002 3.99 (1.51–10.55) 0.005
Female sex 1.05 (0.45–2.46) 0.905 1.72 (0.57–5.23) 0.339
Coronary tortuosity 0.50 (0.27–1.21) 0.123 0.49 (0.17–1.37) 0.173
Hypertension 0.61 (0.28–1.35) 0.22 0.51 (0.20–1.34) 0.173
Diabetes mellitus 0.70 (0.27–1.85) 0.48 0.47 (0.14–1.54) 0.213
Hypercholesterolemia 0.87 (0.40–1.91) 0.73 0.70 (0.26–1.86) 0.473
95% CI, 95% confidence interval; OR, odds ratio.
Table 4. Independent Covariates of the Extent of LV Myocardial Hypoperfusion
in Multivariate Linear Regression Analysis (Multiple R2 = 0.28, p < 0.01)
Univariate analysis Multivariate analysis
Independent variable Beta coefficient p Beta coefficient p Tolerance VIF
Global coronary plaque area (mm2) 0.27 0.005 0.18 0.057 0.852 1.173
Age > 65 years 0.34 < 0.001 0.28 0.003 0.885 1.130
Significant stenosis 0.37 < 0.001 0.31 0.001 0.836 1.196
Coronary tortuosity - 0.16 0.094 - 0.12 0.191 0.886 1.128
Female sex - 0.03 0.747 - 0.06 0.523 0.799 1.251
Hypertension - 0.03 0.792 - 0.05 0.616 0.905 1.105
Diabetes mellitus 0.02 0.843 - 0.03 0.714 0.861 1.161
Hypercholesterolemia - 0.03 0.726 - 0.10 0.308 0.841 1.189
VIF, variance inflation factor.
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chest pain and nonobstructive CAD has demonstrated a high
prevalence of atherosclerosis with positive remodeling and
preserved lumen size.21,22 This emphasizes the limitation of
the present study using angiography to estimate the coronary
artery plaque area, since only the luminal narrowing is vi-
sualized on the angiogram. In addition, it was not possible to
measure plaque area in coronary arteries < 1.5mm in diam-
eter with our method. Consequently, global coronary artery
plaque area may have been underestimated, in particular in
women in our study, due to the combination of more positive
remodeling and smaller coronary artery diameter. Further-
more, angiographic normal reference segments often contain
mild to moderate diffuse atherosclerosis, possibly leading
to an underestimation of the true lumen diameter, and thereby
of the plaque area.23 Still, as demonstrated, reproducibility
of global coronary plaque area measurement by our method
was good.
The prognostic importance of the ischemic burden as-
sessed by contrast echocardiography at rest has been docu-
mented in patients with acute chest pain.11,24 The use of
contrast stress echocardiography in assessment of CAD risk
in menopausal women is currently under evaluation.25 In
patients with myocardial infarction, larger extent of myo-
cardial hypoperfusion by contrast echocardiography at rest
has been demonstrated to predict unfavorable LV remodel-
ing and impaired prognosis.24,26 Similarly, previous studies
assessing myocardial perfusion by magnetic resonance im-
aging have reported increased morbidity, in particular hos-
pitalizations for angina pectoris, in women with chest pain
and nonobstructive CAD.10,27 Consequently, extent and se-
verity of the perfusion abnormalities are important prog-
nosticators in patients with different types of acute coronary
syndromes.
It was recently demonstrated in a numerical simulation
study that coronary artery tortuosity may induce myocardial
ischemia through a reduction in coronary artery perfusion
pressure.28 Typically, coronary artery tortuosity is more
prevalent in women and in patients with hypertension.9 In
this study, tortuosity was indeed more prevalent in women,
but not associated with hypertension. Coronary artery tor-
tuosity was not associated with myocardial hypoperfusion
at rest neither in women nor men. Thus, the clinical rele-
vance of coronary tortuosity in NSTEMI remains to be
established.
Finally, endothelial dysfunction, vessel inflammation and
microvascular disease may all contribute to myocardial hy-
poperfusion in NSTEMI patients with nonobstructive CAD
beyond the global coronary artery plaque area.2,29,30 How-
ever, these factors were not measured in the present study. On
the other hand, hypertension and diabetes, comorbidities
known to be associated with endothelial dysfunction did not
differ between women and men, and also did not predict the
extent of myocardial hypoperfusion in the present study.31
Conclusions
In women and men with NSTEMI, the global coronary
artery plaque area was an important determinant of the se-
verity of myocardial hypoperfusion at rest independent of
presence of significant coronary stenoses. These findingsmay
expand current understanding of NSTEMI in patients with
nonobstructive CAD.
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Background: The underlying mechanisms causing myocardial ischemia in non-obstructive coronary artery dis-
ease (CAD) are still unclear. We explored whether left ventricular hypertrophy (LVH) was associated with myo-
cardial ischemia in patients with stable angina and non-obstructive CAD.
Methods: 132 patients (mean age 63 ± 8 years, 56% women) with stable angina and non-obstructive CAD diag-
nosed as b50% stenosis by coronary computed tomography angiography (CCTA) underwent myocardial contrast
stress echocardiography. Left ventricular (LV) hypertrophy (LVH)was identifiedby LVmass index N46.7 g/m2.7 in
women and N49.2 g/m2.7 inmen. Patientswere grouped according to presence or absence ofmyocardial ischemia
by myocardial contrast stress echocardiography. The number of LV segments with ischemia at peak stress was
taken as a measure of the extent of myocardial ischemia.
Results:Myocardial ischemia was found in 52% of patients, with on average 5 ± 3 ischemic LV segments per pa-
tient. The group with myocardial ischemia had higher prevalence of LVH (23 vs. 10%, p = 0.035), while age, sex
and prevalence of hypertension did not differ between groups (all p N 0.05). Inmultivariable regression analyses,
LVH was associated with presence of myocardial ischemia (odds ratio 3.27, 95% confidence interval [1.11–9.60],
p= 0.031), and larger extent ofmyocardial ischemia (β=0.22, p=0.012), independent of confounders includ-
ing age, hypertension, obesity, hypercholesterolemia, calcium score and segment involvement score by CCTA.
Conclusions: LVH was independently associated with both presence and extent of myocardial ischemia in pa-
tients with stable angina and non-obstructive CAD by CCTA. These results suggest LVH as an independent con-
tributor to myocardial ischemia in non-obstructive CAD.
Clinical trial registration number: ClinicalTrials.gov, identifier NCT018535271.
© 2019 Elsevier B.V. All rights reserved.
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1. Introduction
Management of patients with non-obstructive coronary artery dis-
ease (CAD) and stable angina represents a major clinical challenge
[1,2]. Non-obstructive CAD is a common finding, in particularly among
women [3,4]. During recent years it has been well documented that pa-
tients with non-obstructive CAD have increased cardiovascular morbid-
ity and mortality, contrasting the original conception that it was a
benign condition [2–6]. Myocardial ischemia is characterized by a
mismatch between the myocardial oxygen supply and demand, and
has adverse prognostic implications in patients with CAD [7]. Further,
detection of myocardial ischemia in non-obstructive CAD may help to
identify the patients with increased risk of impaired prognosis [8].
Moreover, the pathophysiologic mechanisms leading to myocardial
ischemia in patients with non-obstructive CAD appear to bemultifacto-
rial. Several factors, including hypertension, atherosclerosis and micro-
vascular dysfunction, have been reported as potential contributors to
myocardial ischemia [1,9,10]. However, the underlying disease mecha-
nisms contributing to myocardial ischemia in the individual patient
may often not be identified during routine diagnostic work-up, and ev-
idence based guidelines for personalized management of patients with
non-obstructive CAD are still missing [1].
Left ventricular hypertrophy (LVH) is the hallmark of hypertension
mediated organ damage and is an independent predictor of both all-
cause mortality and cardiovascular morbidity in general and hyperten-
sive population [11–14]. In hypertensive patients, LVH, in particular the
concentric type, has been associated with presence of symptomatic
myocardial ischemia even with normal coronary angiography [15]. It
has previously been suggested that hypertensive patients with LVH
have a lower threshold for myocardial ischemia and that this may ex-
plain the increased cardiovascular risk [16]. However, the impact of
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LVH, a potential treatment target, on myocardial ischemia in patients
with non-obstructive CAD has not previously been explored. Thus, the
aim of this studywas to assesswhether presence of LVHmay contribute




The Myocardial Ischemia in Non-obstructive Coronary Artery
Disease (MicroCAD) study is a cross-sectional study that prospec-
tively included patients referred to coronary computed tomography
angiography (CCTA) at Department of Heart Disease, Haukeland
University Hospital, Bergen, Norway in the period May 2013 until
November 2014 by experienced cardiologist on a clinical suspicion
of stable angina and that were diagnosed with non-obstructive
CAD. Other inclusion criteria were age N30 years, clinical stable an-
gina, defined as exercise induced angina pectoris and/or dyspnea
for at least 6 months, and at least one cardiovascular risk factor (hy-
pertension, hypercholesterolemia, diabetes, smoking or family his-
tory of premature CAD). Exclusion criteria were clinically unstable
angina, severe valve disease, mechanical valve prosthesis, arrhyth-
mias, severe pulmonary disease and known allergies to ultrasound
contrast.
In total 153 patients were identified and invited, of whom 21 de-
clined participation, leaving 132 patients included in the MicroCAD
study. All participants signed informed consent. The MicroCAD project
was approved by the regional ethical committee andwas performed ac-
cording to the 1975 Declaration of Helsinki. The MicroCAD project is
registered at ClinicalTrials.gov with identifier NCT01853527.
2.2. Cardiovascular risk factors and symptoms
The patients reported cardiovascular risk factors, medical history and
use of medication on a standardized questionnaire. Family history of pre-
mature CADwas considered present if documented CADwas present in a
first-degree relative before the age of 65 years in women and 55 years in
men. Hypercholesterolemia was defined as total serum cholesterol
N6.5 mmol/l or use of cholesterol-lowering treatment. Body mass index
(BMI) was calculated as body weight in kilograms divided by height in
meters squared. Obesity was defined as BMI ≥30 kg/m2. Hypertension
was defined as known hypertension, use of antihypertensive drugs
or high blood pressure at the clinic visit (systolic blood pressure
≥ 140 mm Hg and/or diastolic blood pressure ≥ 90 mm Hg) [17].
Fasting blood samples were collected to measure serum lipid profile,
serum glucose and creatinine. Glomerular filtration rate was esti-
mated by the Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) formula [18].
2.3. Conventional echocardiography
Echocardiographywas performed following a standardized protocol
and interpreted in linewith current joint guidelines of the American So-
ciety of Echocardiography and the European Association of Cardiovas-
cular Imaging [19]. We interpreted the images offline at the Bergen
Echocardiography Core Laboratory blinded to clinical data. All images
were proof-read by the same experienced reader (MTL). Left ventricular
(LV) mass was calculated by Devereux's equation and indexed for
height in meters in the allometric power of 2.7. We defined LVH by
the prognostically validated sex specific cut-off values of LV mass
index (LVMi) N46.7 g/m2.7 in women and N49.2 g/m2.7 in men [12,20].
LV ejection fraction was calculated by Simpson's biplane method. Rela-
tive wall thickness was calculated as posterior wall thickness/LV inter-
nal radius ratio and considered increased if ≥0.43 [19]. LV geometry
was classified into four groups based on the presence of LVH and normal
or increased relative wall thickness [19]. Accordingly, normal LV geom-
etrywas defined as no LVHandnormal relativewall thickness, concentric
remodeling as no LVH and increased relative wall thickness, concentric
LVH as LVH and increased relative wall thickness, and eccentric LVH as
LVH and normal relative wall thickness [19].
2.4. Myocardial contrast echocardiography for myocardial perfusion
Myocardial contrast echocardiography was performed using
real-time low-mechanical index imaging and destruction replen-
ishment following current guidelines [21]. Ultrasound contrast
agent (SonoVue, Bracco, Milan, Italy) was given intravenously as
1 ml bolus followed by 1 ml/h infusion with a rotating infusion
pump (VueJet, Bracco, Milan, Italy). Apical 2-, 3- and 4-chamber
views were used to score wall motion and myocardial perfusion at
rest and at peak dobutamine stress, defined as 85% of maximum
age predicted (200 – age) heart rate during stress echocardiography
[21]. Wall motion was scored visually as normal or abnormal, and
myocardial perfusion as normal or delayed in the individual 17-
segments of the LV. Stress induced myocardial ischemia was de-
fined as presence of delayed contrast replenishment 2 heart beats
after flash at peak stress in any LV segment. The number of LV seg-
ments with delayed perfusion at peak stress was taken as a measure
of the extent of myocardial ischemia.
2.5. Coronary computed tomography angiography and non-obstructive
coronary artery disease
CCTA was performed by a 256-slice dual source scanner (Somatom
Definition Flash, Siemens, Germany) with electrocardiographic (ECG)
-triggered acquisitions. Patients with heart rate N60 beats per minute
were given metoprolol intravenously (1 mg/ml, maximum 20 mg)
until heart rate was ≤60 beats per minute. The patients received non-
ionic contrast intravenously as 80–115 ml iomeprol 400 mg I/ml
(Iomeron®, Bracco, Milan, Italy) according to body weight. All patients
received 0.4 mg sublingual nitroglycerin in order to optimize image
quality. Experienced readers analyzed all images for detection of coro-
nary artery stenosis using amodified 20-segment American Heart Asso-
ciation model [22]. Non-obstructive CAD was defined as presence of ≥
one stenosis with lumen diameter reduction 1–49% in any coronary ar-
tery segment. CCTAwas revised in all patients where we detectedmyo-
cardial ischemia in order to confirm diagnosis of non-obstructive CAD.
Segment involvement score was calculated as the total number of coro-
nary segments with atherosclerotic plaque [23].
2.6. Statistical analysis
Data analysis was performed using IBM SPSS Statistics version 24
(IBM Corporation, Armonk, NY, USA). The sample size was determined
in order to have 80% power with statistical level of 0.05 to find 50% dif-
ferences in prevalence of LVH between patients with and without myo-
cardial ischemia, including an anticipated dropout rate of 5%. The study
population was grouped into patients with and without myocardial is-
chemia. We compared groups by unpaired Student's t-test for continu-
ous variables and Chi-Square test for categorical variables. The results
are presented as mean ± standard deviation or median and interquar-
tile range for continuous variables and number and percentages for cat-
egorical variables. Predictors of myocardial ischemia were assessed in
uni- and multivariable logistic regression models and reported as odds
ratio (OR) with 95% confidence intervals (CI). Independent covariables
of the extent of myocardial ischemia were identified by uni- andmulti-
variable linear regression analysis with standardized coefficients (β). A
p b 0.05 was considered significant in all analyses.
2 I. Eskerud et al. / International Journal of Cardiology 286 (2019) 1–6
3. Results
3.1. Clinical characteristics and myocardial contrast stress echocardiography
All 132 study participants had symptomatic stable angina. Prior
stress testing with exercise ECGwas performed in 115 (89%) of the par-
ticipants, and a total of 79 (67%) of the testswere reported to be negative
or inconclusive due to low exercise capacity or left bundle branch block,
leaving 36 patients (31%) with a positive exercise ECG. Myocardial
ischemia by contrast stress echocardiography was found in 69 patients
(52%), and among patients with a positive exercise ECG, 67% were diag-
nosed with myocardial ischemia by contrast stress echocardiography.
The median time from CCTA to myocardial contrast echocardiography
was 133 days (interquartile range 98–188 days). The group with myo-
cardial ischemia had a 2-fold higher prevalence of LVH (Table 1), in par-
ticularly concentric LVH (Fig. 1). The groups did not differ in age, sex,
prevalence of hypertension or antihypertensive treatment, however obe-
sity was less common in the group with myocardial ischemia (Table 1).
Table 1
Clinical characteristics of the total study population and of groups of patients with and without myocardial ischemia.
Total (n = 132) Ischemia (n = 69) No ischemia (n = 63) p
Age (years) 63 ± 8 63 ± 9 62 ± 8 0.317
Female sex (%) 56 54 59 0.555
BMI (kg/m2) 27.7 ± 4.5 27.2 ± 4.1 28.2 ± 4.8 0.206
Obesity (%) 24 16 32 0.032
Hypertension (%) 75 81 68 0.077
Diabetes (%) 13 12 13 0.919
Current cigarette smoking (%) 16 13 19 0.341
Family history of premature CAD (%) 64 58 70 0.192
Hypercholesterolemia (%) 48 54 41 0.156
Systolic blood pressure (mm Hg) 135 ± 16 135 ± 17 135 ± 16 0.795
Diastolic blood pressure (mm Hg) 79 ± 13 79 ± 13 79 ± 13 0.998
Heart rate (bpm) 69 ± 12 71 ± 13 68 ± 12 0.303
Serum glucose (mmol/L) 5.9 ± 1.6 5.9 ± 1.0 6.0 ± 2.0 0.727
Estimated GFR (mL/min/1.73 m2) 86 ± 14 87 ± 15 85 ± 13 0.389
Total serum cholesterol (mmol/L) 5.0 ± 1.3 5.1 ± 1.4 5.0 ± 1.2 0.719
Serum HDL cholesterol (mmol/L) 1.5 ± 0.4 1.5 ± 0.5 1.5 ± 0.4 0.896
Serum LDL cholesterol (mmol/L) 3.2 ± 1.2 3.3 ± 1.3 3.2 ± 1.0 0.718
Serum triglycerides (mmol/L) 1.47 ± 0.96 1.55 ± 0.84 1.39 ± 1.08 0.340
Acetylsalicylic acid (%) 47 57 36 0.026
Statin (%) 38 40 36 0.627
Antihypertensive treatment (%) 58 59 56 0.729
Beta blocker (%) 30 23 36 0.126
Calcium channel blocker (%) 18 24 12 0.094
LV internal diastolic dimension (mm) 45.2 ± 5.5 45.0 ± 5.5 45.3 ± 5.5 0.764
LV internal systolic dimension (mm) 29.2 ± 5.3 29.0 ± 5.4 29.4 ± 5.2 0.678
Septal thickness (mm) 11.8 ± 2.0 12.3 ± 2.1 11.3 ± 1.8 0.003
Posterior wall thickness (mm) 9.3 ± 1.9 9.4 ± 2.1 9.1 ± 1.6 0.476
LV ejection fraction (%) 62 ± 7 63 ± 6 60 ± 7 0.019
LVMi (g/m2.7) 40.1 ± 9.3 42.1 ± 9.7 37.9 ± 8.4 0.009
LVH (%) 17 23 10 0.035
Relative wall thickness 0.42 ± 0.11 0.42 ± 0.11 0.41 ± 0.10 0.487
Calcium score (HU) 42(14–107) 47(16–127) 37(11–83) 0.264
Number of diseased coronary arteries 1.6 ± 1.8 1.7 ± 0.8 1.5 ± 0.7 0.084
Multi-vessel disease (%) 54 60 48 0.168
Segment involvement score 2.6 ± 1.6 2.8 ± 1.8 2.4 ± 1.3 0.149
BMI, bodymass index; CAD, coronary artery disease; bpm, beats per minute; GFR, glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; LV, left ventric-
ular; LVMi, left ventricular mass index; LVH, left ventricular hypertrophy; HU, Hounsfield units.
Fig. 1. Left ventricular geometry in patients with and without myocardial ischemia. Figure legend: LVH, Left ventricular hypertrophy. *p b 0.05 between groups.
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Coronary artery calcium score and segment involvement score (SIS),
reflecting extent and severity of non-obstructive CAD, did not differ be-
tween the groups (Table 1).
By myocardial contrast stress echocardiography, 89% of patients
reached age predicted maximal heart rate at peak stress. Nine of the 14
patients (65%) with lower than predicted maximal heart rate at peak
stress hadmyocardial ischemia. Patients with andwithout myocardial is-
chemia had similar peak systolic blood pressure and heart rate (121±23
vs. 123 ± 22 mm Hg, p = 0.616 and 132 ± 10 vs. 132 ± 11 beats per
minute, p = 0.846). Fifteen patients (11%) had abnormal wall motion at
peak stress. In 11 of these 15 patients wall motion abnormality was in
the region supplied by the left anterior descending artery. The average ex-
tent of stress induced myocardial ischemia was 5 ± 3 LV segments. Wall
motion abnormalities were significantly correlatedwith perfusion abnor-
malities during stress echocardiography, inwhich13 (87%) of the patients
with wall motion abnormalities also had perfusion abnormalities (p =
0.006). However, most patientswith perfusion abnormalities had no con-
comitant wall motion abnormalities.
3.2. Covariates of myocardial ischemia
In univariable logistic regression analysis, myocardial ischemia was
associated with presence of LVH and absence of obesity (Table 2). Myo-
cardial ischemia remained independently associated with presence of
LVH inmultivariable analysis even after adjusting for age, hypertension,
obesity, hypercholesterolemia, calcium score and SIS (Table 2).
In univariable linear regression analyses, larger extent of myocardial is-
chemiawas associatedwith presence of LVH, hypertension andhypercholes-
terolemia(Table3). Inmultivariable linear regressionanalysis, largerextentof
myocardial ischemia remained associated with LVH independent of hyper-
tension, obesity, hypercholesterolemia, calcium score and SIS (Table 3).
4. Discussion
4.1. Myocardial ischemia and non-obstructive CAD
The present study demonstrates that about 50% of patients with sta-
ble angina and non-obstructive CAD have myocardial ischemia that can
be detected by myocardial contrast stress echocardiography. The pres-
ent results add to current knowledge by identifying the association of
LVHwith presence and extent of myocardial ischemia in these patients,
independent of presence of hypertension.
Traditionally, myocardial ischemia has been perceived as secondary
to coronary artery disease which directly obstructs blood flow to the
myocardium [9,24]. However, we and others have previously demon-
strated that myocardial ischemia may be present also in non-
obstructive CAD [8,15,25]. The association between myocardial ische-
mia and LVH iswell known as one of several mechanisms thatmay con-
tribute to myocardial ischemia in patients with non-obstructive CAD, in
addition to coronary vasospasm, coronary microvascular and endothe-
lial dysfunction [1,10,26]. For instance, subendocardial ischemia and re-
duced myocardial blood flow have been detected by single photon
computed tomography and positron emission tomography in patients
with hypertrophic cardiomyopathy and in diabetes patients with LVH
[27–29]. Reversible and irreversible ischemia was also detected in 35%
of patients with LVH and exercise induced ST-depression, and was par-
ticularly prevalent in patients with concomitant CAD [30]. Further, in
linewith our results, it has previously been reported that LVHmay con-
tribute to lower the ischemic threshold in patients with hypertension
and clinical evidence of CAD [31].
In animal studies, LVH has been suggested to contribute to myocar-
dial ischemia through several mechanisms, such as reduced myocardial
capillary density, increased LVfilling pressure and increasedmyocardial
oxygen demand [32,33]. In patientswith ST elevationmyocardial infarc-
tion, presence of LVH has been associated with higher incidence of mi-
crovascular obstruction as well as larger myocardial infarct size by
cardiac magnetic resonance imaging [34]. The present results add to
this by demonstrating that LVH may contribute to myocardial ischemia
also in patients with stable angina and non-obstructive CAD.
As demonstrated, presence of hypertensionwas associatedwith larger
extent ofmyocardial ischemia independent of LVH in our study. This sug-
gests that hypertension contributes to myocardial ischemia through sev-
eral mechanisms beyond the higher LV mass. As recently pointed out by
Bairey Merz et al., hypertension may also influence myocardial perfusion
in non-obstructive CAD through impaired vasomotion, endothelial dys-
function, atherosclerosis, reduced coronary microvascular density and
thickened and stiffened microvessels with poor autoregulatory capacity
[1].
In addition to LVH and hypertension, absence of obesity and pres-
ence of hypercholesterolemia were associated with a larger extent of
myocardial ischemia in our study. The inverse association between obe-
sity and myocardial ischemia was unexpected, and could not be ex-
plained by group-differences in sex or smoking. On the other hand,
elevated total cholesterol is a well-established risk factor of CAD [35].
Furthermore, myocardial ischemia was not detected in all patients
with LVH, suggesting that the etiology ofmyocardial ischemia wasmul-
tifactorial also in our study.
Although the present study is small, our results may have potential
important clinical implications for management of patients with non-
obstructive CAD and stable angina. Current guidelines for management
of patients with stable angina have pointed out the need for scientifi-
cally based management of non-obstructive CAD [36]. In particular,
echocardiographic detection of LVH and myocardial ischemia may
offer targets for a more personalized management of patients with
non-obstructive CAD, pointing to the value of multimodality imaging
in these patients. Moreover, antihypertensive treatment is associated
with normalization of LV geometry and improved prognosis [11,37].
Our results also emphasize the importance of cardiovascular risk
Table 2
Covariables of myocardial ischemia identified in logistic regression analyses.
Variable Univariable analysis Multivariable analysis
OR 95% CI p OR 95% CI p
LVH 2.87 1.04–7.88 0.041 3.19 1.04–9.76 0.043
Age (years) 1.02 0.98–1.06 0.315 0.99 0.94–1.04 0.623
Hypertension 2.05 0.92–4.59 0.080 2.24 0.97–5.65 0.059
Obesity 0.41 0.18–0.94 0.035 0.38 0.15–1.00 0.049
Hypercholesterolemia 1.65 0.83–3.28 0.157 1.98 0.92–4.28 0.083
Calcium score 1.00 0.99–1.01 0.461 1.00 0.99–1.01 0.874
Segment involvement score 1.18 0.94–1.49 0.159 1.19 0.87–1.65 0.280
Female sex 0.81 0.41–1.62 0.555
Diabetes 0.95 0.33–2.70 0.919
Current smoking 0.62 0.23–1.67 0.344
OR, odds ratio; CI, confidence interval; LVH, left ventricular hypertrophy.
Table 3






β p β p
LVH 0.19 0.034 0.23 0.010
Age (years) 0.002 0.984 −0.18 0.056
Hypertension 0.20 0.021 0.25 0.005
Obesity −0.16 0.069 −0.18 0.044
Hypercholesterolemia 0.18 0.039 0.24 0.006
Calcium score 0.09 0.329 0.12 0.233
Segment involvement score 0.12 0.176 0.06 0.519
Female sex −0.11 0.191
Diabetes 0.09 0.325
Current smoking −0.09 0.335
Multiple R2 = 0.18, p = 0.001.
LVH, left ventricular hypertrophy.
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control. In line with this, it has recently been demonstrated that in pa-
tients with non-obstructive CAD and myocardial infarction, the risk of
new major cardiovascular events is predicted by established cardiovas-
cular risk factors, including hypertension, diabetes and smoking [38].
Further, patients with non-obstructive CAD less often receive secondary
preventivemedication aftermyocardial infarction [39]. Accordingly, op-
timal medical treatment of non-obstructive CAD should be verified in
prospective clinical studies.
4.2. Study limitations
We have selected a population with high risk of cardiovascular
disease and our results cannot necessarily be generalized to a general
angina population. The cross-sectional study design precludes iden-
tification of any causal relation between LVH and myocardial ische-
mia. The proportion of women was lower than what could be
expected [40]. This might be explained by a referral bias, as only pa-
tients referred to CCTA by a cardiologist due to suspected CAD were
eligible for inclusion. It is well documented from the Coronary CT An-
giography Evaluation for Clinical Outcomes: An International Multi-
center (CONFIRM) registry that women referred to CCTA have a
higher pre-test probability of CAD then men [41]. In addition, the
small study size did not allow stratification of the results by sex due to
insufficient statistical power. However, our study population reflects a
large group of patients in clinical practice who currently lack evidence-
based guidelines for diagnostic work-up and management.
5. Conclusion
In patients with stable angina and non-obstructive CAD on CCTA,
myocardial ischemia was found in half of the patients and was inde-
pendently associated with presence of LVH. Our results suggest LVH
as a potential treatment target in patients with stable angina and
non-obstructive CAD to be explored in further clinical studies.
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